TW299230B - - Google Patents

Download PDF

Info

Publication number
TW299230B
TW299230B TW82101311A TW82101311A TW299230B TW 299230 B TW299230 B TW 299230B TW 82101311 A TW82101311 A TW 82101311A TW 82101311 A TW82101311 A TW 82101311A TW 299230 B TW299230 B TW 299230B
Authority
TW
Taiwan
Prior art keywords
patent application
weight
cns
ministry
item
Prior art date
Application number
TW82101311A
Other languages
Chinese (zh)
Inventor
Mesa Milagros Garcia
Original Assignee
Dalmer Lab Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dalmer Lab Sa filed Critical Dalmer Lab Sa
Application granted granted Critical
Publication of TW299230B publication Critical patent/TW299230B/zh

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Description

A6 299230 B6 五、發明説明(/ ) (請先閲讀背面之注意事項再填寫本頁) 本發明涉及高级脂族伯醇的混合物,其中含有22到 38個磺原子,尤其是24到34值磺原子的醇,更具體 地說,含有 24、 26、 27、 28、 29、 30、 32 和34値碩原子的直鍵醇。 該混合物各批之間的各個醇的相對組成顯示出很好的 重覆性。 根據本發明,得到的高级脂族伯酵潺合物(下面稱為 Μ. Η. P. A. A.)具有待殊的藥理性能,因此可以 在藥物製劑中作為活性組成,用於降低瞻固酵、抗血小板 、抗血栓形成和/或抗局部缺血,以及用於對抗藥物引起 的潰堪和改菩男性性功能。 蔗糖蠟及其天然來源,蔗泥,一直是人們閬注的對象 ,這不僅是因為它們的工業用途,而且也由於它們的化學 組成。甘蔗中的蟠含量在0.1%至0. 3%之間,依品 種而異。 在製産工業加工中,僅僅40%的蟠含置被稀釋到甘 蔗汁中,其餘的則損失於蔗渣裡。 經濟部中央櫟準局8工消费合作社印製 這從40%中,95%被蔗泥吸收,由蔗泥製得粗蟠 。這種蟠由酯、醛、酮、烴類、脂肪酸和游離醇構成,各 组成的數量取決於甘蔗作物的品種和來源以及製取蟠所用 的技術。 若干作者已研究過這甘蔗副産物中得到的直鍵脂族醇 以了解其成分和主要待點。從各類锻中製取不同組合的化 本紙張尺度適用中國國家標準(CNS)甲4规格(210 X 297公釐) 經濟部中央標準屬貝工消費合作社印製 A6 B6 五、發明説明(1) 合物已有報導(J.A.Lanberton 等,1959 ; Australian J 〇 u r n a 1 〇 f C h e m i s t r y , 13,2 δ 1 2 6 8,以及 Η 〇 r n A . a n d Mart ic JS, 19 5 7 ; Journal of Science Food andA6 299230 B6 V. Description of the invention (/) (Please read the notes on the back before filling out this page) The present invention relates to a mixture of higher aliphatic primary alcohols, which contains 22 to 38 sulfon atoms, especially 24 to 34 sulfonate Atomic alcohols, more specifically, straight-chain alcohols containing 24, 26, 27, 28, 29, 30, 32 and 34 atoms. The relative composition of the alcohols between batches of this mixture showed good repeatability. According to the present invention, the obtained high-grade aliphatic primary fermentation complex (hereinafter referred to as Μ.Η.PAA) has special pharmacological properties, so it can be used as an active component in pharmaceutical preparations to reduce anti-platelet enzymes and antiplatelets , Anti-thrombosis and / or anti-ischemia, as well as to fight the collapse caused by drugs and improve male sexual function. Sucrose wax and its natural source, cane puree, have always been the object of attention, not only because of their industrial use, but also because of their chemical composition. The content of panax in sugarcane is between 0.1% and 0.3%, depending on the species. In the industrial manufacturing process, only 40% of the pan content is diluted into sugar cane juice, and the rest is lost in bagasse. Printed by the Central Oak Quasi-Bureau of the Ministry of Economic Affairs of the 8th Industrial Consumer Cooperative. This is from 40%, 95% of which is absorbed by the sugarcane mud and made from the sugarcane mud. This flat is composed of esters, aldehydes, ketones, hydrocarbons, fatty acids and free alcohols, and the amount of each component depends on the variety and source of the sugarcane crop and the technology used to make the flat. Several authors have studied the straight-chain aliphatic alcohol obtained from this sugarcane by-product to understand its composition and main points of interest. Different combinations of chemical papers produced from various types of forging are applicable to the Chinese National Standard (CNS) A4 specifications (210 X 297 mm). The central standard of the Ministry of Economic Affairs is printed by the Beigong Consumer Cooperative Society A6 B6 V. Description of invention (1 ) Compounds have been reported (JALanberton et al., 1959; Australian J urna 1 〇f C hemistry, 13, 2 δ 1 2 6 8 and Η 〇rn A. and Mart ic JS, 19 5 7; Journal of Science Food and

Agriculture 10, 571),他們提出一種甘蔗表皮蟠製取脂 族醇的方法,其作法是氫氣化鉀酵溶液均勻皂化,接著將 不能皂化的物質酯化,再進行分子蒸餾。 這報導過通過高效高真空蒸皤柱分離醇潺合物的另一 種方法。這種高真空下的蟠蒸餾用來將羰基化合物化學分 離並使用石油醚萃取剩餘的捶。將溶劑蒸發,剩餘成分 化,以便通過氣化鋁層析進一步分離。最後,經過加碱水 解得到醇,然後在乙醇中再结晶,熔點範圍為80至82 。 一種從動物蟠和植物蟠得到高级脂族伯醇的方法是基 於將脂族酯皂化,接著採用適當的溶劑,通過壓力為60 —300千克/平厘米,溫度在25 — 1 00TC之間的亞 臨界態和超臨界態的C02流體萃取醇混合物,該法表明 ,在低溫下依賴於溶解度和壓力妥化,可以進行選擇性萃 取。將這一方法用於甘蔗蠟,可以得到5%的C2 到C 3 6的醇的混合物。 另一種設計(Inada S, Furukawa K.,Masui T., Honda k. , Wgasawara J. and tsubikanato G. , 1 9 8 5 ; 回收高级脂族正伯醇的方法,日本專利60 — 1 1 95 1 4號)提出了一種很類似的萃取蠟的方法,該方法以帶有 本紙張尺度適用中困國家標準(CNS)甲4规格(210 X 297公货) (請先面之注意事項再填寫本頁) —裝. 訂· 299230 A6 B6 五、發明説明(」>) (請先閱讀背面之注意事项再填寫本頁) 乙烯的亞臨界和超臨界狀態C02流醱為基礎。也有人報 道過用處在亞臨界和超臨界狀態的流匾從温合物中分離有 機化合物。從分析的角度看,所有這些都是有價值的方法 ,但是由於使用管柱色層分析和分子蒸皤造些全是不經濟 的方法,妨礙了大規模生産。 本發明的目的之一是從粗裂蟠和精製蟠逭兩種甘蔗锻 中得到,分離和純化有24到34傾碩原子的高级脂族伯 醇(M.H.P.A.A.)。 本發明的方法是基於用碱或碱土金屬氫氣化物,尤其 是用低分子量的,待別是纳、鉀和鈣的氫氧化物濃溶液將 預先熔化的甘蔗蟠均質皂化的方法。 經濟部t央襟準扃8工消费合作社印製 氫氣化物溶液的濃度必須使相睡的氫氣化物與要處理 的蟠的重量比超過5%,尤其是從8%至25妬,待別是 從15%到25%。皂化過程持缠30分鐘以上,尤其是 從2到5小時。將這一步得到的固體置於固一液萃取器中 ,用適當的有機溶劑選擇性萃取Μ. Η. P. A. A., 有機溶劑選自3到8餾碩原子的酮,1到5傾碩原子的醇 ,6到9個碩原子的烴,鹵仿及芳族化合物,例如苯及其 衍生犓,包括它們的混合物。用於本發明的一些優蓮的溶 劑是以下幾種:丙酮、甲乙酮、戊酮、己酮、庚酮、2_ 甲基戊酮、乙酵、甲醇、2—丙醇、丁醇、叔丁酵、戊烷 、己烷、庚烷、辛烷、氣仿、1, 2 —二氣乙烷、二氛甲 烷、三氛乙烷、1, 2, 3_三氛丙烷、苯、甲苯、苯酚 本紙張尺度適用中困國家標準(CNS)甲4规格(210 X 297公釐〉 經濟部中央標準局貝工消费合作社印製 A6 B6__ 五、發明説明() 、對甲基甲苯及其它。 萃取在5到10小時的時間内進行。然後,用上述的 溶劑或其混合物将産物逋鑀结晶。産率約為30%,而Μ .Η. P. A. Α.的純度逹到80%至98%,特別是 從90%至98%。這樣得到的Μ. Η. P· A. A.是 由22到38艟碩原子的醇組成。逭是一種灰白色的混合 物,熔點在76. 5和84. 之間。為了用熔凝二氣 化矽毛細管柱通過氣相色層分析分析Μ· Η. P. A. A ,用N -甲基_N —三甲基矽烷基三氟乙醍胺(MST F A )衍生化合物。 與先前報導的相比,本發明提出的這甘镜蟠中獲取Μ .Η. P. A. Α.的方法具有某些優點。這些優點之一 是加工時間短。本發明的另一個優點是用這種方法可以達 到的高産率(接近30%重量),相比之下,先前介绍的 S ho等人的結果報導産率低於5%。所提出的方法的S 一個優點與可以達到Μ. Η. P· A. A.的純度有闋( 接近9 8%),它比目前工》水平所報導的高出很多。因 此,本發明提出的方法比Inada等(日本專利60-1 1 95 14)和 Hagiwara Y.(日本專利 62 — 87537) 的方法更簡單,而且更適合於大規模生産。 表1列出了根據本發明從甘蔗蟠得到的Μ· Η· P· A. A.潺合物的定性和定量組成。 t 表 1:在藥物製劑中使用的Μ. Η. Ρ. Α· A组合物 本纸張尺度適用中困a家標準(CNS)甲4规格(210 X 297公釐) -----------------------裝------tr-----二 (請先閲讀背面之注意Ϋ項再塡寫本頁> A6 B6 五、發明説明() 的 定 性及定量 组成範圍 組 分 在混 合物 中 的比率 1 一 二 十 四 烷 醇 0 . 5 - 5 . 0 % 1 一 二 十 烷 醇 5 . 0 - 1 5 . 0 % 1 — 二 十 七 烷 醇 0 . 5 - 5 . 0 % 1 — 二 十 八 烷 醇 5 0 . 0 — 8 0 . 0 % 1 一 二 十 九 烷 醇 0 . 5 - 3 . 0 % 1 — 二 十 烷 醇 6 . 0 - 2 0 . 0 % 1 響 三 十 二 烷 醇 1 . 0 - 1 0 . 0 % 1 麵 三 十 四 烷 醇 0 . 0 - 2 · 5 % 表2列出了從甘蔗蟠分離出的一種優選的Μ. Η. P .A. A.組合物,表3列出了最優選的Μ. Η. P. A .A .组合物。 表 2:在藥物裂劑中使用的Μ. Η. P. A. A的優選 的定性與定量範園 组 分 在混合物中的比率 ----------------1--------裝------4? (請先閲讀背面之注意事項再填寫本頁) 經濟部中央標準局w工消费合作社印製 1 -二十四烷酵 0 . 5 _ 1 . 0 % 1 一二十六烷醇 6 . 0 - 8 . 0 % 1 一二十t烷醇 2 . 5 - 3 . 5 % 1 _二十八烷醇 6 0. 0 - 7 0. 0 % 1 -二十九烷醇 0 . 5 _ 1 . 0 % 1 _三十 烷醇 10. 0 - 15. • 0 % 1 一三十二烷醇 4 . 5 - 6 . 0 % 本纸張尺度適用中國國家標準(CNS)甲4規格(210 X 297公;Ϊ ) A6 B6 五、發明説明()Agriculture 10, 571), they proposed a method for preparing aliphatic alcohols from the sugarcane epidermis, which is to uniformly saponify the potassium hydroxide fermentation solution, then esterify the non-saponifiable substances, and then perform molecular distillation. This reported on another method for separating alcohol compounds by high-efficiency high vacuum distillation column. This pan distillation under high vacuum is used to chemically separate the carbonyl compounds and use petroleum ether to extract the remaining thumps. The solvent was evaporated, and the remainder was componentized for further separation by vaporized aluminum chromatography. Finally, the alcohol is hydrolyzed by adding alkali, and then recrystallized in ethanol, with a melting point ranging from 80 to 82. A method for obtaining higher aliphatic primary alcohols from animal flats and plant flats is based on the saponification of the aliphatic ester, followed by the use of an appropriate solvent, through a pressure of 60-300 kg / cm2, and a temperature between 25-1 00TC The critical and supercritical CO 2 fluids extract alcohol mixtures. This method shows that selective extraction can be performed at low temperatures depending on solubility and pressure refining. Using this method for sugarcane wax, a 5% C2 to C3 6 alcohol mixture can be obtained. Another design (Inada S, Furukawa K., Masui T., Honda k., Wgasawara J. and tsubikanato G., 1 9 8 5; method for recovering higher aliphatic n-primary alcohol, Japanese Patent 60 — 1 1 95 1 No. 4) A very similar method of wax extraction is proposed. The method applies the specifications of the national standard (CNS) A 4 (210 X 297 public goods) with the paper size (please pay attention to the precautions before filling in this Page) — Packing. Ordered · 299230 A6 B6 V. Description of the invention (">) (Please read the precautions on the back before filling this page) Ethylene is based on the subcritical and supercritical C02 stream. It has also been reported that flow plaques in subcritical and supercritical states have been used to separate organic compounds from warm compounds. From an analytical point of view, all of these are valuable methods, but the use of column chromatography and molecular steaming are all uneconomical methods that hinder mass production. One of the objects of the present invention is to obtain and to separate and purify a higher aliphatic primary alcohol (M.H.P.A.A.) with 24 to 34 atom atoms from two types of sugar cane forging, coarse cracked and refined flat. The method of the present invention is based on the method of homogenizing saponification of pre-melted sugarcane flats with alkali or alkaline earth metal hydroxides, especially low molecular weight, concentrated hydroxide solutions of sodium, potassium and calcium. The concentration of the hydrogen hydride solution printed by the Ministry of Economic Affairs of the Ministry of Economic Affairs must be such that the weight ratio of the sleeping hydrogen hydride to the flats to be processed exceeds 5%, especially from 8% to 25%. 15% to 25%. The saponification process is held for more than 30 minutes, especially from 2 to 5 hours. Place the solid obtained in this step in a solid-liquid extractor, and selectively extract Μ.Η.PAA with an appropriate organic solvent, the organic solvent is selected from 3 to 8 distillate atom ketone, 1 to 5 decanter atom alcohol , Hydrocarbons with 6 to 9 atoms, haloform and aromatic compounds, such as benzene and its derivatives, including mixtures thereof. Some of the solvents used in the present invention are the following: acetone, methyl ethyl ketone, amyl ketone, hexanone, heptanone, 2-methylpentanone, ethyl alcohol, methanol, 2-propanol, butanol, tert-butanol , Pentane, hexane, heptane, octane, gas imitation, 1, 2-two gas ethane, two atmosphere methane, three atmosphere ethane, 1, 2, 3_ three atmosphere propane, benzene, toluene, phenol The paper standard is applicable to the National Standard (CNS) A4 specifications (210 X 297 mm). A6 B6__ printed by the Beigong Consumer Cooperative of the Central Standards Bureau of the Ministry of Economic Affairs. 5. Description of the invention (), p-methyltoluene and others. Extracted at 5 It takes up to 10 hours. Then, the product is crystallized with the above solvent or a mixture thereof. The yield is about 30%, and the purity of M.Η.PA Α. Is 80% to 98%, especially From 90% to 98%. The M.H.P · AA obtained in this way is composed of alcohols with 22 to 38 atoms. Yau is an off-white mixture with a melting point between 76.5 and 84. In order to use melting Condensation two gasification silicon capillary column was analyzed by gas chromatography, Μ · Η.PA A, using N-methyl_N-trimethylsilyl trifluoroethylene amide (MST F A) Derivative compounds. Compared with the previously reported, the method of obtaining M.H. PA Α. From the paniculata in the present invention has certain advantages. One of these advantages is the short processing time. Another of the present invention The advantage is the high yield (approximately 30% by weight) that can be achieved with this method. In contrast, the results of the previously introduced Sho et al. Report a yield of less than 5%. The advantages of the proposed method are: The purity of M.H.P · AA can be reached (nearly 98%), which is much higher than that reported by the current engineering level. Therefore, the method proposed by the present invention is higher than that of Inada et al. (Japanese Patent 60-1 1 95 14) and Hagiwara Y. (Japanese Patent 62-87537) are simpler and more suitable for large-scale production. Table 1 lists the M · Η · P · AA compounds obtained from sugarcane flats according to the present invention Qualitative and quantitative composition. T Table 1: Μ.Η.Ρ.Α · A composition used in pharmaceutical preparations. The paper size is applicable to the standard of CNS A 4 (210 X 297mm) ----------------------- installed ------ tr ----- two (please read the note Ϋ on the back first before writing page > A6 B6 V. Description of the invention () Qualitative and quantitative composition range The ratio of the components in the mixture 1 monotetracosyl alcohol 0.5-5.0% 1 monocosyl alcohol 5.0-1 5 . 0% 1 — octacosanol 0.5 .5-5. 0% 1 — octacosanol 5 0. 0 — 8 0. 0% 1 monocosanol 0.5 .3-3. 0% 1 — eicosanol 6. 0-2 0. 0% 1 ring tridecanol 1. 0-1 0. 0% 1 surface tridecanol 0. 0-2 · 5% Table 2 lists For a preferred M.H.P.AA composition isolated from sugarcane flats, Table 3 lists the most preferred M.H.P.A.A. compositions. Table 2: The ratio of the preferred qualitative and quantitative Fan Yuan components used in the drug splitting agent in the mixture ---------------- 1-- ------ Installed ------ 4? (Please read the precautions on the back before filling in this page) Printed by the Central Bureau of Standards of the Ministry of Economics and Industry and Consumer Cooperatives 1 -tetracosane yeast 0. 5 _ 1. 0% 1-hexacosanol 6. 0-8. 0% 1-icosanoyl alcohol 2.5-3. 5% 1 _ octacosanol 6 0. 0-7 0. 0 % 1 -cosacosyl alcohol 0.5 .1 _ 1. 0% 1 _ triacontanol 10. 0-15. • 0% 1 monotricosyl alcohol 4.5 .6. 0% of the paper size Applicable to China National Standard (CNS) A4 specifications (210 X 297 g; Ϊ) A6 B6 V. Description of invention ()

經濟部中央標準局β工消费合作社印S 1 — 三 十 四 院 酵 0 • 5 輕 2 » 5 % 表 3 • 在 藥 物 製 剤 中 使 用 的 Μ • Η • P • Λ • A 組 合 物 最 佳 定 性 與 定 置 範 園 組 分 在 混 合 物 中 的 fcfc 率 1 — 二 十 四 垸 酵 0 » 8 土 0 • 1 % 1 — 二 十 — 烷 酵 6 • 7 士 0 » 3 % 1 — 二 十 七 烷 酵 3 • 0 土 0 -· 3 % 1 — 二 十 八 烷 醇 6 5 • 6 士 3 • 4 % 1 — 二 十 九 烷 醇 0 * 7 土 0 • 1 % 1 — 三 十 烷 酵 1 2 * 5 土 0 * 6 % 1 — 三 十 二 院 酵 5 * 0 土 0 ♦ 4 % 1 — 三 十 四 垸 酵 0 擊 8 土 0 • 1 % 工 • Η • P • A • A 及 其 藥 物 製 剤 可 以 给 人 類 和 動 物 施 用 〇 Μ • Η • P • A • A 的 Β 劑 置 隨 所 治 療 的 疾 病 和 生 命 睦 的 實 際 狀 態 而 有 很 大 受 化 t 但 通 常 是 在 毎 天 1 壓 1 0 0 毫 克 之 間 » 最 好 是 約 3 — 2 0 毫 克 〇 Μ > Η * P • A • A 可 以 服 或 非 腸 道 給 藥 〇 優 m 的 途 徑 是 Ρ 服 膜 衣 的 錠 剤 以 及 粒 劑 或 m 襄 〇 藥 物 裂 劑 中 含 有 作 為 活 性 组 成 的 0 • 5 % 到 1 5 % 重 置 的 Μ • Η • P • A • A 〇 這 一 劑 量 是 通 過 將 Μ • Η • P • A • A 與 各 種 賦 形 劑 ( 例 如 凝 集 劑 、 朋 解 劑 、 m m 劑 > 滑 動 劑 ) 或 只 與 填 料 混 合 得 到 的 〇 這 些 賦 形 爾 中 包 括 乳 糖 Λ 玉 米 澱 粉 蔗 糖 、 硬 脂 酸 m m 晶 m 維 素 、 交 脚 的 羧 甲 (嫌先閲$面之注意事項再場寫本頁) -裝- 訂· 本紙張尺度適用中國國家標準(CNS)甲4規格(210 X 297公釐) 299230 A6 B6 五、發明説明() 基铨維素鈉、明膠、乙驩鄰苯二甲酸纖維素、二氣化鈦, 供錠劑用的待種滑石粉和聚乙二醇。 甘蔗蟠的降脂效果已用大鼠得到了證實(Fukuda,甘 蔗蟠對大鼠血淸和肝脂的影鬱;化學文摘,106, 17, 13 74 13 P;以及 Sho H.等,19845,Okinawan 甘蔗皤和脂肪 酵對大鼠血淸和肝脂的彩留,J. Nutri. vitaDinol, 30, 6, 553-553) 〇 最初,甘蔗蠟對血淸和肝脂的彩堪用餵飼高含量植物 和動物脂肪的雄性Wistar大鼠作了研究。逭些作者發現, 向規定食物的脂肪中加入0. 5%甘蔗蟠大大降低了饑飼 植物或動物脂肪的大鼠的血淸甘油三脂,但僅在後一情形 胺固醇含置才明顯降低,而肝脂的含量不受影響。因此, 這些作者斷定,甘蔗蟠具有降血脂作用。 另一方面,Sho Η等人(1984)研究了冲® 甘蔗皤對於箱食含0. 5%這種皤的食物的大鼠的血淸及 肝脂的影繼,他們發現血淸和肝的胶固醇含置均願著降低 。镒管如此,當在動物食物中使用從同一種蟠中得到的脂 肪醇時,K固酵含量無明顯變化。因此,他們排除了蟠的 降脂作用是由於這些酵造成的。 經濟部中兴標毕房wcH消费合作社印製 (請先閲f面之注意事项再填寫本買> 但是,幾年之後 ShiBura S.,Hagesawa. Τ., Takano S.和Susuki T. ( 1937:鬨於二十八烷醇對小鼠運動持久 性的影 ίδ ; N u t r i t i 〇 n R e ρ 〇 r t s I n t. 3 6,1 0 2 9 - 1 0 3 8)用 * 進行體力活動和館食富含含二十八烷醇食物的小鼠矸究了 本紙張尺度通用中國國家標率(CNS)甲4规格(210 X 297公釐) A6 ___B6 五、發明説明() (請先閲<^*之注意事項再填寫本頁) 二十八烷醇的影響。他們發現•從甘庶蠟中分離出來的二 十八烷醇顯著降低肝中的甘油三酯和膝固酵的含置,而血 淸中R有甘油三酯含量才明顯降低。他們斷定,從甘蔗蠼 中分離出的二十八烷醇有降脂作用,這與上迷的Sho Η等 人的先前结果不同。 同樣,曾經提出另一種高级脂族伯醇,二十六烷醇,也 具有抗血脂作用,雖然據報導霈要很高的爾量才得到這種 效果(10 — 3 0 毫克 / 千克/天)(HagiwaraY.1987 :用於含二十六烷酵的抗血脂劑治療高血壓、動脈硬化、 糖尿病、心臓病、和肥胖;日本專利A62 — 09932 3 ) 〇 現在已有認為是安全、有效和耐受性良好的各種商品 降脂藥物,但是它們大多産生各種不良的副作用。因為降 脂藥物必須長期服用。所以逭一點很重要。 經濟部中央標準局工"費合作社印製 例如,二甲苯氣庚酸降低血淸甘油三酯,增高高度脂 蛋白胺固醇(HDL-C)含fi,並且使血淸8S固酵略有 減小,但是已報導有幾種不良作用。例如,5腸作用,加 上腹痛、腹瀉、噁心、暱吐和氣脹等已有報導。另外,在 用二甲苯氣庚酸治療的患者中當發現頭痛、頭昏、視力模 糊、陽萎、性欲減退和肝力能反常,例如轉氨醑、乳酸脱 氫醏、肌酸磷酸激醑和驗性碟酸酶增高。同樣,督袞竭病 人不能服用。 丙丁酚是具有抗氣化劑性質的另一種降脂藥物,它使 -10 - 本紙張又度適用中國S家標準(CNS)甲4规格(210 X 297公釐〉 經濟部中央標準渴S工消费合作社印»i< A6 _ B6_ 五、發明説明() 血淸》固醇和低密度脂蛋白睡固酵(LDL — C)適度減 少《但是,它的降脂作用的一倕缺黏是它降低了HDL— C的含量。另外,t報導它有幾種不良作用,例如約10 %的患者的胃腸失調現象,以及心電圖有相當大的變化。 常用的其它降脂藥物是消臛胺和降膝寧P它們是有效 的優秀降膽固醇藥物,強烈地降低血淸8S固酵和LDL-C,但是會增高甘油三酯含量。這些藥物會引起幾種甭腸 症狀,主要是便秘。治療的順應性一般較低,因為有不良 的症狀,而且它們是不易服用的藥劑,箱要高達12至2 0克/天的劑置才達到所要求的效果。另外,曾有人報導 它們與其它藥物,例如毛地黄毒苷,有不良的化學相互作 用。Printed by the Central Bureau of Standards of the Ministry of Economic Affairs β Industrial Consumption Cooperative Society S 1 — Sanyuanyuan Fermentation 0 • 5 Light 2 »5% Table 3 • Μ • Η • P • Λ • A used in pharmaceutical preparations The fcfc rate of the components of the fixed Fanyuan in the mixture 1 — twenty-four fermented yeast 0 »8 soil 0 • 1% 1 — twenty — alkane leaven 6 • 7 ± 0» 3% 1 — heptacosane leaven 3 • 0 soil 0-· 3% 1 — octacosanol 6 5 • 6 ± 3 • 4% 1 — behenadecanol 0 * 7 soil 0 • 1% 1 — triaconanol 1 2 * 5 soil 0 * 6% 1 — Thirty-two Houses of Fermentation 5 * 0 soil 0 ♦ 4% 1 — Thirty-four fields of leaven 0 hit 8 soil 0 • 1% work • Η • P • A • A and its medicines can be given to humans and Animal administration 〇M • Η • P • A • A Β agent placement is greatly affected by the actual condition of the disease and life to be treated t However, it is usually between 1 mg and 100 mg per day »Preferably about 3-20 mg 〇Μ > Η * P • A • A can be taken or parenteral administration 〇 优 m The route is Ρ The film-coated tablets and granules or medicaments contain 0 • 5% to 15% as the active component of the reset Μ • Η • P • A • A 〇 This dose is obtained by applying Μ • Η • P • A • A and various excipients (such as coagulant, disintegrant, mm agent> slip agent) or only mixed with fillers. These excipients include lactose Λ corn starch sucrose, stearin Acid mm crystal m vitamins, intermediary carboxylic acid (to read the precautions on the $ surface before writing this page) -installation- order · The paper size is applicable to China National Standards (CNS) A4 specifications (210 X 297 ) 299230 A6 B6 V. Description of the invention () Sodium quantite sodium, gelatin, cellulose acetate phthalate, titanium dioxide, talcum powder to be used for tablets and Glycol. The lipid-lowering effect of sugarcane flats has been confirmed in rats (Fukuda, the shadow depression of sugarcane flats on blood and liver fat in rats; Chemical Abstracts, 106, 17, 13 74 13 P; and Sho H. et al., 19845, Okinawan sugarcane scallion and lipase on the color retention of blood and liver fat in rats, J. Nutri. VitaDinol, 30, 6, 553-553) 〇 Initially, the color of sugarcane wax on blood and liver fat was high Male Wistar rats with vegetable and animal fat content were studied. Some authors found that adding 0.5% sugarcane to the fat of the prescribed food greatly reduced the blood triglyceride in rats starving for plant or animal fat, but only in the latter case was the amine sterol content apparent Reduced, and the content of liver fat is not affected. Therefore, these authors concluded that sugarcane flat has a hypolipidemic effect. On the other hand, Sho Η et al. (1984) studied the effect of Chong® sugarcane jelly on the blood and hepatic fat of rats fed 0.5% of this jelly food. They found that blood and liver Gum alcohol content is willing to reduce. This is true for the ytterbium tube. When the fatty alcohol obtained from the same type of panax is used in animal food, there is no significant change in the K-solid enzyme content. Therefore, they ruled out that the lipid-lowering effect of pan was caused by these enzymes. Printed by the Ministry of Economic Affairs ZTE Standard Bifang wcH Consumer Cooperative (please read the precautions on the f side before filling in this book) However, a few years later ShiBura S., Hagesawa. Τ., Takano S. and Susuki T. (1937: Coax the effect of octacosanol on the persistence of exercise in mice ίδ; Nutriti 〇n R e ρ rts I n t. 3 6, 1 0 2 9-1 0 3 8) Use * for physical activity and pavilion Mice who ate foods rich in octacosanol studied the specifications of this paper. The general Chinese National Standard Rate (CNS) A 4 specifications (210 X 297 mm) A6 ___B6 5. Invention description () (please read <; ^ * Precautions and then fill out this page) The influence of octacosanol. They found that octacosanol isolated from ganshu wax significantly reduced the content of triglycerides and knee zymosin in the liver However, the content of triglyceride in R was only significantly reduced. They concluded that the octacosanol isolated from the sugarcane has a lipid-lowering effect, which is different from the previous results of the obsessed Sho Η et al. The same , Another high-level aliphatic primary alcohol, hexacosanol, has also been shown to have anti-lipidic effects, although it has been reported that centipede is very high This effect can only be obtained in small amounts (10-30 mg / kg / day) (HagiwaraY.1987: used for anti-lipid agents containing hexadecane fermentation to treat hypertension, arteriosclerosis, diabetes, heart disease, and obesity; Japanese Patent A62 — 09932 3) 〇 There are various commercial lipid-lowering drugs that are considered to be safe, effective and well tolerated, but most of them produce various adverse side effects. Because lipid-lowering drugs must be taken for a long time, it is very important Printed by the Ministry of Economic Affairs, Central Standards Bureau's "Cooperative Society", for example, xylene gas enanthate reduces blood triglycerides, increases the height of lipoprotein amine sterol (HDL-C) containing fi, and makes blood solid 8S solid fermentation. It has been reduced, but several adverse effects have been reported. For example, the 5 intestinal effect, plus abdominal pain, diarrhea, nausea, vomiting, and flatulence have been reported. In addition, in patients treated with xylene gas enanthate Found headache, dizziness, blurred vision, impotence, decreased libido, and abnormal liver energy, such as transamin, dehydrolactate, creatine phosphate, and testosterone. Equally, patients with dysfunction cannot Taken. Probucol is another lipid-lowering drug with anti-gasification agent properties, which makes -10-this paper again applicable to China S Home Standards (CNS) A 4 specifications (210 X 297 mm). Printed by S Industry and Consumer Cooperatives »i < A6 _ B6_ V. Description of the invention () Blood stagnation sterol and low-density lipoprotein sleep solid fermentation (LDL-C) moderately reduced" However, one of its lack of viscosity It reduces the content of HDL-C. In addition, t reported that it has several adverse effects, such as gastrointestinal disorders in about 10% of patients, and considerable changes in electrocardiograms. The other commonly used lipid-lowering drugs are chloramidamine and Jiangyining P. They are effective and excellent cholesterol-lowering drugs, which strongly reduce blood cholesterol 8S solid enzyme and LDL-C, but will increase triglyceride content. These drugs can cause several bowel symptoms, mainly constipation. The compliance of the treatment is generally low because of the adverse symptoms, and they are not easy to take medicines, the box should be up to 12 to 20 grams per day to achieve the desired effect. In addition, it has been reported that they have undesirable chemical interactions with other drugs, such as digitoxin.

Lovastatin 是” Statins” 中的一種,屬於 HMGC0 A還原酶的抑製劑,從而有效地降低血清躇固醇和LDL 一C的含量,它也適度地増高HDL—C並減少甘油三酯 。已有人報導過此種藥物的幾種副作用。例如,主要的副 作用是肌病、肌酸磷酸激酶的低度至中度增加和血淸轄氨 醑永久性增加,這常常在停止治療後受成不可逆的。肌病 主要發生於用免疫抑制藥物(如二甲苯氧庚酸或烟酸)進 行伴隨治療的患者。另外,曾報導過用Lovas tat in治療和 患者中,敏感的患者有諸如皮疹、瘙癀、頭痛和嚴重的肌 肉損傷等副作用,結果導致肌溶解。再者,曾報導過在實 驗室動物中發生與藥物有問的軍九萎縮和肝腫瘤。 -11- 本紙張尺度逯用t S國家標準(CNS)甲4規格(210 X 297公釐) (請先閲讀背面之注意事項再f本頁) i裝. 訂. 經濟部中央標準局S工消費合作社印製 A6 _ _ _B6__ 五、發明説明() 類似地,S ievas tat in和 Pravas tat in是另外二種” Statins”, 它們按照與Uvas tat in同樣的機裂起作用, 顯示出近似相同的降低膝固醇的效果。對這些患者報導的 副作用與Uvastatin治療的患者相同,但是據稱程度較輕 ,據報導,用Simvastatin和Pravastatin治療的患者有便 秘、氣脹、噁心、頭痛、疲努、皮下皮疹和彩轚肌酸磷酸 激酶的肌病。 另一方面,曾經提到某些降脂藥物治療降低了在高血 壓病人中常見的血小板過度聚集的傾向,實驗數據已顯示 了由這些化合物調節的抗聚集作用。儘管如此,僅僅某些 降胺固醇藥物顯示出這種性霣。正如己提到的,動脈粥樣 硬化是動眤内膜多種多樣變化的綜合结果,這些受化含括 脂類、複合的碩水化合物.血和血液産物,纖維组鏃及鈣 沈澱物的局部累積,常常還伴有内側受化。因此,這一定 義表明動脈粥樣硬化是一健多因素的過程,不僅佳以高血 脂作為危險因子。 因此,在對動脈粥樣硬化和發展起作用的各因子之間 ,血小板聚集佔有很重要的地位。血小板釋放微含有活性 花生四烯酸,它代謝變化成環形内過氧化物。它們主要披 轉化成環形的内過氣化物,最终受成為血拴烷AZ ) TxA z ),這是一種很強的血管收缩劑和血小板聚集劑。有各 種化合物可以誘發血小板聚集,例如匾原、腺苷二磷酸和 腎上腺素及其它。因此,各種以”體内”、”醞外”或” -12- (請先閲讀背面之注—項再塡窝本頁) .丨装. 訂· 本紙張尺度適用中國國家標準(CNS)甲4规格(210 X 297公:^ ) 經濟部中央櫺準局RX消费合作社印$ A6 _B6_ 五、發明説明() 試管内”方式試驗假定的抗血小板藥物的效力的實驗,通 常是檢驗所述藥物對由這些化合物誘發的血小板聚集的彩 這些試驗也用來試驗健康的志願人員和患有常常誘發 聚集過度的病人,例如患有血朦固醇過多和糖尿病的病人 的血小板聚集。在這些試驗之中,醪原誘發血小板聚集是 最常使用的。例如,靜脲内注射膠原導致”活鳢内”不可 逆的血管内血小板聚集,血小板聚集醱進入血管撖循環, 從而減少循環的血小計數,同時增加血漿中的丙二醛(M DA)S度。另外,在某些動物中,注射®原會誘發血栓 形成而迪成死亡。在這些楔式中,抗血小板藥物一般防止 血小板含量減少和丙二醛(MDA)濃度的增加,以及由 匾原導致的死亡。 某些具有防止血小板聚集作用的藥物可用來治療血栓 病、心肌梗死和中風,但是它們並非都有這些優點。另一 方面,有的抗血栓藥物主要通過溶解過程影鬱血液疑集, 而不是對血小板聚集起作用,例如_激酶和尿激藤。 因為局部缺血性心血管病、中風和血管末稍阻塞病症 是動脈粥樣硬化的主要後逋症,所以試驗了幾種_物也能 通過對這些過程中涉及的其它現象的作用而阻止道些併發 症,則必定對治療這些病人有利。同樣,ΤχΑζ含量的 降低不僅與抗血小板和抗血栓形成作用有鼷,而且也與抗 局部缺血作用有闢。抗局部缺血藥物的窠學篩選通常包括 -13- 本纸張尺度適用中國困家標準(CNS)甲4規格(210 X 297公» ) -------------------------裝------訂------4 (請先閲讀背面之注意事項再填寫衣頁) 299230 A6 _B6_ 五、發明説明() 評估它們對誘發的腦部局部缺血的作用p例如,替有人報 導過各種藥物對大鼠腦局部缺血的保護作用,包括抑制環 氣酶催化的反應的某些非甾族消炎藥物(NSA ID)以 及血拴合成酶抑製劑和前列膝環素類似物(Pglz)( Borzeix MG 和 Cahn J . , 1988, 新的化學上代謝穩定的前列膝環素類似物對鼠類短暫性大 腦血量滅少的作用;Prostag 1 and.i ns 3 5,5,653 — 664·)。 其它的實驗方式,例如用滎古沙土鼠實驗誘發的腦部 局部缺血,也常常採用。 乙醒水揚酸(ASA)是在實驗模型和人醞中顯示出 抗血小板、抗血栓形成和抗局部缺血性能的一種化合物。 它是在治療急性心肌梗塞和中風以及防止血栓栓塞紊亂方 面懕用最廣的一種藥物。AS A的作用受到眾所周知的它 對花生四烯酸代謝時的一種關鍵酶(琛氧酶)的抑制作用 的支時。因此,ASA使血淸中血栓烷A2 ( Τ X A 2 ) 含量明顯地大大減少,後者是公認的血管内皮病理生理因 子,逭解釋了ASA的上述作用。 經濟部中央標準局β:工消费合作社印製 (#先閲讀背面之注$項再填寫本頁) 但是,因為ASA的抑制作用是在環氣爾澳度上發揮 作用,所以不僅TxA2含量降低,而且前列腺琛素(P g Ιζ )的含置&降低•後者是藥理性質與ΤχΒζ相反 的一種化合物。另一方面,考慮到ASA抑制了前列腺素 (条列E)的合成,它會由於阻碍前列腺素的细胞保護作 -14- 本紙張尺度適用中國國家標準(CNS)甲4規格(210 X 297公货〉Lovastatin is a kind of "Statins", which is an inhibitor of HMGC0 A reductase, which can effectively reduce the content of serum sterols and LDL-C. It also moderately increases HDL-C and reduces triglycerides. Several side effects of this drug have been reported. For example, the main side effects are myopathy, low-to-moderate increase in creatine phosphokinase, and permanent increase in blood pressure, which is often irreversible after treatment is stopped. Myopathy mainly occurs in patients undergoing concomitant treatment with immunosuppressive drugs (such as xyloxyheptanoic acid or niacin). In addition, it has been reported that Lovas tat in treatment and patients, sensitive patients have side effects such as rash, pruritus, headache and severe muscle damage, resulting in myolysis. Furthermore, it has been reported that Junjiu atrophy and liver tumors related to drugs have occurred in laboratory animals. -11- The size of this paper is t S National Standard (CNS) Grade 4 (210 X 297 mm) (please read the precautions on the back and then this page) i install. Order. S Ministry of Economic Affairs Printed by the consumer cooperative A6 _ _ _B6__ V. Description of the invention () Similarly, Sievas tat in and Pravas tat in are the other two kinds of “Statins”, which act according to the same machine split as Uvas tat in, showing approximately the same The effect of reducing knee sterol. The side effects reported in these patients are the same as those treated with Uvastatin, but are reportedly milder. It is reported that patients treated with Simvastatin and Pravastatin have constipation, flatulence, nausea, headache, fatigue, subcutaneous rash and creatine Phosphokinase myopathy. On the other hand, it has been mentioned that certain lipid-lowering drug treatments reduce the tendency of platelets to excessively aggregate, which is common in patients with high blood pressure, and experimental data have shown an anti-aggregation effect regulated by these compounds. Nonetheless, only certain anti-steroidal drugs show this sex disorder. As already mentioned, atherosclerosis is a comprehensive result of a variety of changes in the endometrium of the animal. These compounds include lipids, complex water compounds, blood and blood products, fibrous components and local calcium deposits. Accumulation is often accompanied by medialization. Therefore, this definition indicates that atherosclerosis is a multi-factorial process, and it is not only best to use hyperlipidemia as a risk factor. Therefore, among the factors that contribute to atherosclerosis and development, platelet aggregation plays an important role. Platelet release contains slightly active arachidonic acid, which metabolizes and changes into ring-shaped peroxides. They are mainly converted into ring-shaped internal gasification compounds and eventually become thromboxane AZ) TxA z), which is a strong vasoconstrictor and platelet aggregation agent. There are various compounds that can induce platelet aggregation, such as plaque, adenosine diphosphate and epinephrine and others. Therefore, all kinds of "in vivo", "incubation" or "-12-" (please read the note on the back-item and then this page). 丨 installed. Ordered · This paper size applies to China National Standard (CNS) A 4 Specifications (210 X 297 g: ^) Printed by the RX Consumer Cooperative of the Central Bureau of Economic Development of the Ministry of Economic Affairs. $ A6 _B6_ V. Description of the invention () In-vitro test method to test the effectiveness of the hypothetical antiplatelet drug, usually to test the drug These tests on platelet aggregation induced by these compounds are also used to test platelet aggregation in healthy volunteers and patients who often induce hyperaggregation, such as patients with hyperglycemia and diabetes. Among these tests, mashogen-induced platelet aggregation is the most commonly used. For example, injecting collagen into urea causes irreversible platelet aggregation in blood vessels, and platelet aggregation enters the blood vessel circulation, thereby reducing circulating small blood counts and increasing the degree of malondialdehyde (M DA) in the plasma. . In addition, in some animals, injecting ® originally induced thrombosis and Dicheng died. In these wedges, antiplatelet drugs generally prevent the reduction of platelet content and the increase in malondialdehyde (MDA) concentration, as well as death caused by plaque. Certain drugs that prevent platelet aggregation can be used to treat thrombosis, myocardial infarction, and stroke, but they do not all have these advantages. On the other hand, some antithrombotic drugs mainly suppress the blood suspicion through the lysis process, rather than affecting platelet aggregation, such as _ kinase and urinary vine. Because ischemic cardiovascular disease, stroke, and terminal obstruction of blood vessels are the main posterior symptoms of atherosclerosis, testing several substances can also prevent the pathogenesis by acting on other phenomena involved in these processes. These complications must be beneficial to the treatment of these patients. Similarly, the reduction in ΤχΑζ content not only has anti-platelet and anti-thrombotic effects, but also anti-ischemic effects. The screening of anti-ischemic drugs usually includes -13- This paper scale is applicable to the China Sleepless Family Standard (CNS) A4 specification (210 X 297 gongs ») -------------- ----------- installed ------ order ------ 4 (please read the precautions on the back before filling in the clothing page) 299230 A6 _B6_ V. Description of the invention () Evaluate them Effect on induced cerebral ischemia p For example, it has been reported that various drugs have protective effects on rat brain ischemia, including some non-steroidal anti-inflammatory drugs (NSA ID) that inhibit the reaction catalyzed by cyclooxygenase And thromboxane synthase inhibitors and prostacyclin analogs (Pglz) (Borzeix MG and Cahn J., 1988, the new chemically metabolically stable prostacyclin analogues reduce transient brain blood volume in rats The role; Prostag 1 and. Ns 3 5,5,653 — 664 ·). Other experimental methods, such as cerebral ischemia induced by the Xinggu gerbil experiment, are also often used. Acetylsalicylic acid (ASA) is a compound that shows antiplatelet, antithrombotic and anti-ischemic properties in experimental models and human incubation. It is one of the most widely used drugs in the treatment of acute myocardial infarction and stroke and in preventing thromboembolic disorders. The role of AS A is influenced by its well-known inhibition of a key enzyme (chen oxygenase) in arachidonic acid metabolism. Therefore, ASA significantly reduced the content of thromboxane A2 (TXA2) in blood plasma, which is a recognized pathophysiological factor of vascular endothelium, and explained the above-mentioned role of ASA. Printed by the Central Standards Bureau of the Ministry of Economic Affairs: Printed by the Industrial and Consumer Cooperative (#Read the note on the back of the page before filling in this page) Moreover, the content & reduction of prostaglandin (P g Ιζ) • The latter is a compound whose pharmacological properties are opposite to ΤχΒζ. On the other hand, considering that ASA inhibits the synthesis of prostaglandins (Section E), it will prevent the cell protection of prostaglandins due to -14- This paper scale is applicable to the Chinese National Standard (CNS) A 4 specifications (210 X 297 goods>

娌濟部中央標準房员工消费合作社印S A6 _B6_ 五、發明説明() 用而造成胃損傷。逭是對ASA報導的主要副作用,邸, 胃炎、费潰瘍及有闋的失讁現象。 本發明的目的之一是用一種公眾丢棄物24至34傾 硪原子的Μ. Η. P.A.A.作為藥物裂劑。 本發明的另一目的是使用相當低剤量的24至34傾 硪原子的Μ. Η. P. A.A.作為降低膝固醇藥物製劑 的活性组成。 本發明的又一目的是將Μ. Η. P. A. A.用於抗 血小板、抗局部缺血或抗血拴形成的蕖物裂剤中,以顯示 Μ. Η. P. A. A.的抗血小板聚集的作用,逭已在” 體外”和”醱内”模型中以及在人體中的一糸列不同實驗 中得到證實》 本發明的再一目的是證實Μ. Η. P.A.A.對實 驗誘發的局部缺血的保護作用》 本發明的另一目的是證實Μ. Η. P.A.A.和最 常用於大腦局部缺血治療的A S A之間有藥理相互作用。 結果表明在Μ. Η. P.A.A.和ASA的抗血小板、 抗血栓形成和抗局部缺血效能之間声相同作用。 本發明還有一傾目的是證實Μ. Η. P. A.A.顯 著減少被阿斯匹林、乙酵、消炎痛、化合物C4880 ( 西格焉公司)和其它在所治療人醱中産生S潰瘍的蕖物所 造成的贾潰瘍。曾經報導,乙酵誘發的费潰瘍主要與作為 生理因素的ΤχΑζ的增加有闋,而C4800誘發的潰 -15- 本纸張尺度通用t困a家標準(CNS)甲4规格(210 X 297公釐) ----------------【-------裝------訂 (請先聞讀背面之注$項再填寫本頁) 熳濟部中央櫺準屬貝工消费合作社印* A6 __B6_ 五、發明説明() 瘍主要與血淸素激活的機制有關,雖然不能排除ΤχΑζ 在雄體生殖方面的作用。g —方面,ASA誘發的费潰瘍 與ASA産生的對前列腺素(E糸列)合成的抑制有關, 因為前列腺素對费粘膜有细胞保護作用。已經證實,Tx Α2與Ps ΙΖ比在爾粘膜中作為一種整醞的内源機制起 重要的作用。 另一方面,如前所述,某些降低朦固酵的橥物損寄男 性性功能。例如,曾報導用安妥明和二甲苯《庚酸治療的 患者性欲減退和陽萎。 相反,本發明的另一目的是證實Μ. Η. P . A . A .不僅不損害男性性功能,而且還增強人和動物的性功能 。例如,曾提到有許多高K固醇患者在臨床試驗中進行治 療期間性功能增強。這一效果與涉及控制性欲和性行為的 主要激素一一軍酮在血清中的含量變化無蘭。 軍酮被認為是哺乳動物中控制性欲的主要性激素。已 經有人報導,對於性功能只需要閾值水平的畢酮。過多的 蓽酮並不導致雄性性功能的進一步增強。但是最近以來已 經證簧,同樣的睪酮水平包含著不同的激素釋放或給與方 式,這可能導致對雄性性功能的不同彩鬌。逭表明在這方 面仍存在相反的意見。 另一方面,哺乳動物中雄性性行為包括不同的階段: 性欲、陰莖勃起、性欲高潮和射精,它們是由複雜的神經 内分泌機制控制的。例如,這一行為是由作用在末稍效應 -1 6 - ----------------一-------裝-------ΤΓ (請先閲讀背面之注意事項再堉寫衣頁> 本紙張尺度適用中國國家標準(CNS)甲4规格(210 X 297公* > A6 _B6__ 五、發明説明() (請先聞1!^面之注意^項再5^本頁) 器上的睪丸激素的穉放,作用在主要位於中央基式下視丘 匾域的中植神經糸统上的激發及反餓機制以決定。多巴胺 能途徑和血淸素激活途徑都控制性功能。 最後,並已證實,一氣化氮(NO)在海棉《處的釋 放是陰莖勃起的關鍵機制。因此,Μ. Η. P. A. A. 改進雄性性功能的作用可以用還未完全明瞭的另外的機制 解釋》 最後,在關於Μ. Η. P. A. A.全貌的整傾描鎗 中,與目前已知的藥物柑比,它的極好的安全性和耐受性 代表了一種重要的優點。例如,用齧齒動物、兔子、獵鬼 犬和猴子進行的急性、亞慢性和悝性研究中,表明没有與 藥物有闢毒性。另外,它在家兔或小鼠中既無任何的誘變 作用,也沒有致畤作用。服用Μ. Η· P. A. A.兩代 以上的大鼠未影鬱胎兒發冒,也不影湛生殖活動。最後, 對小鼠進行24鏟月的致癌性研究也表明,M.H. P. A.A.沒有毒性和致癌作用。 短期和長期臨床試驗也説明這種治療極其完全和具有 棰好的耐受性。 經濟部中央樑準房8工消费合作社印® 本發明的目的將在以下實施例中詳細說明。這些實施 例將不限制本發明的範圍。 實施例1 取1000克精裂甘蔗®在100—110¾下熔化 ,加入溶在1 50毫升水中的200克氳氣化鉀。在攪拌 -17- 本紙張尺度適用中囲國家標準(CNS)甲4规格m〇 X 2S7公釐) A6 B6 五、發明説明() 下保持此過程5小時。在固 劑由此過程得到的固體中萃 小時。將得到的萃取液在室 A.由其中结晶,在甲乙围 的醇潺合物;純度為94. 80. 5 和 82. 5TC 之間 Μ. Η. P. A. A.的定 表4:所得Μ. Η. P. A 组 分 <請先閲$面之注+W-项再$本買> 一 液 萃 取 条 統 中 以 庚 烷 作 為 溶 取 Μ • Η • P • A • A * 1 2 溫 下 冷 却 » Μ • Η • P • A • 中 重 結 晶 〇 得 到 多 達 2 8 5 克 7 0 % 〇 混 合 物 的 溶 黏 範 臞 在 〇 表 4 列 出 了 用 此 方 法 得 到 的 性 和 定 ft 组 成 〇 A 的 定 性 和 定 置 组 成 各酵的百分含置 •-裝_ 熳濟部中央橒準扃興工消费合作社印製 訂- 1 一二十四烷酵 1 _二十六院酵 1 -二十t烷酵 1 一二十八烷醇 1 _二十九院醇 1 一三十烷醇 1 一三十二烷醇 1 一三十四烷醇 實施例2 將2千克粗製甘蔗蟠在 溶解在2 0 0毫升水中的3 缠此皂化過程4小時。用氛 取条统中萃取Μ. Η. P. 0.81 7.00 2.81 6 5.09 0.67 12.43 5.05 0.84 85 - 1001C下熔化,加入 00克氫氣化鈉,在攪拌下持 仿作為溶劑在常規的固一液萃 A . A . 1 0小時,將所得的 18- 本紙張尺度適用中國國家標準(CNS)甲4规格(210 X 297公* ) A6 B6 五、發明説明() 萃取液在室溫下冷却,所得的固醞在甲醇中重结晶,最後 在氛仿/甲乙酮混合物中重结晶。得到純度總計9 2. 5 2% 的 Μ. Η. P. A. A. 405 克。Μ. Η. P. A .A.的溶黏範圍從79. 0至80. 51::表5列出了用 此方法得到的Μ. Η. Ρ·Α·A.的定性和定置组成。 表5:所得Μ. Η. P. A. A·的定性和定性組成 组 分 各醇的百分含量 (請先Μ讀背面之注意事項再9^本1> _二十四烷醇 一二十六烷酵 0.87 6.84 .丨裝. 絰濟部中央標準房βτ工消費合作社印« 3.08 6 2.92 0.80 12.66 4.65 0.70 1 -二十t烷醇 1 一二十八烷酵 1 一二十九焼醇 1 _三十烷醇 1 —三十二院酵 1 一三十四烷酵 實施例3 將溶解在7升水中的1 2千克氫氣化鈣加到5 0千克 預先在1 00 — 1 20它下熔化的精製甘蔗蟋中。此皂化 過程在攪拌下進行7. 5小時。在固一液萃取条統中用乙 酵作溶W萃取Μ. Η. P.A.Α.12小時。將所得的 萃取液在室溫下放置冷却,而後將固匾在氛仿中重结晶。 得到純度為 93. 77% 的 Μ. Η. P. A. Α. 13. -19- 本紙張尺度通用中國國家標準(CNS)甲4规格(210 X 297公釐) 訂- A6 _B6_ 五、發明説明() 7千克。該混合物的熔黏範圍為80. 0-82. 0C。 表6列出了用此方法得到的Μ. Η. P. A. A.的定性 與定量組成。 表6:所得Μ. Η. P. A. A.的定性和定量組成 組 分 各酵的百分含量 (請先聞讀背面之注意事項再填寫本頁) 1 一二十四烷醇 0 . 7 1 1 一二十六焼醇 6 . 8 8 1 一二十七烷酵 3 . 0 6 1 一二十八烷酵 6 4. 7 0 1 _二十九烷醇 0 . 6 2 1 一三十烷酵 12. 0 1 1 _三十二院醇 5 . 0 9 1 一三十四烷醇 0 . 7 0 實施例4 將8. 6千克溶在4. 5升水中的氫氧化鈣加到5 裝· 訂- 1 經濟部中央標準局R工消费合怍社印製The Ministry of Economy, Central Standard Housing, Employee and Consumer Cooperatives printed S A6 _B6_ V. Description of the invention () Causes stomach injury due to use. Liao is the main side effect reported on ASA, such as gastroenteritis, Fei ulcer and loss of symptoms. One of the objects of the present invention is to use a public discard 24 to 34 p.m. atomic M.H.P.A.A. as a drug splitting agent. Another object of the present invention is to use a relatively low amount of 24 to 34 tilt atoms of M.H.P.A.A. as the active composition for reducing knee sterol pharmaceutical preparations. Another object of the present invention is to use Μ.Η.PAA in anti-platelet, anti-ischemia or antithrombosis formation of phlegm to show the anti-platelet aggregation effect of Μ.Η.PAA. It was confirmed in the "in vitro" and "internal" models and in a series of different experiments in the human body. "Another object of the present invention is to confirm the protective effect of Μ.Η.PAA on experimentally induced ischemia." Another purpose is to confirm the pharmacological interaction between M.H. PAA and ASA, which is most commonly used in the treatment of cerebral ischemia. The results indicate that there is an acoustically identical effect between the antiplatelet, antithrombotic and anti-ischemic efficacy of M.H.P.A.A. and ASA. The present invention is also intended to confirm that Μ.Η.PAA significantly reduced by aspirin, ethyl yeast, indomethacin, compound C4880 (Siger Yan company) and other treatment of human ulcers produced S ulcers Caused by Jia ulcers. It has been reported that the ulcer induced by E.coli is mainly related to the increase of ΤχΑζ as a physiological factor, and the ulcer induced by C4800 -15- This paper standard general standard (CNS) A 4 specification (210 X 297 Ali) ---------------- 【------- installed -------- ordered (please read the $ item on the back and then fill in this page) 熳Printed by the Beibei Consumer Cooperative Cooperative Society of the Central Ministry of Economic Affairs * A6 __B6_ V. Description of the invention () The ulcer is mainly related to the mechanism of hemagglutinin activation, although the role of TχΑζ in male reproduction cannot be excluded. g — On the one hand, ASA-induced Fischer's ulcer is related to the inhibition of prostaglandin (E Shile) synthesis produced by ASA, because prostaglandins have a cytoprotective effect on Fischer's mucosa. It has been confirmed that Tx A2 and Ps IX play an important role in the mucosa as a contemporaneous endogenous mechanism. On the other hand, as mentioned earlier, some of the lowering substances that reduce zymogens impair male sexual function. For example, there have been reports of hyposexuality and impotence in patients treated with antomin and xylene. On the contrary, another object of the present invention is to confirm that M.H.P.A.A. not only does not impair male sexual function, but also enhances the sexual function of humans and animals. For example, it has been mentioned that many patients with high K sterols have increased sexual function during treatment in clinical trials. This effect has nothing to do with the change in serum levels of the main hormone involved in controlling libido and sexual behavior, military ketone. Army ketone is considered to be the main sex hormone in mammals to control libido. It has been reported that only a threshold level of ketone is needed for sexual function. Too much iperone does not lead to further enhancement of male sexual function. However, it has been proven recently that the same testosterone level contains different hormone release or administration methods, which may lead to different color effects on male sexual function. YI indicated that there are still opposing views in this regard. On the other hand, male sexual behavior in mammals includes different stages: libido, penile erection, orgasm, and ejaculation, which are controlled by complex neuroendocrine mechanisms. For example, this behavior is caused by acting on the final effect -1 6----------------- 一 ------- pretend ------- Γ ( Please read the precautions on the back first and then write the clothing page.> This paper scale is applicable to the Chinese National Standard (CNS) A 4 specifications (210 X 297 g **) A6 _B6__ 5. Description of the invention () (please smell 1! ^ Note ^ item 5 ^ this page) The release of testosterone on the organ is determined by the excitation and anti-hunger mechanism of the mid-planter nerve system mainly located in the central base of the hypothalamus. Both pathways and heme activation pathways control sexual function. Finally, it has been confirmed that the release of nitric oxide (NO) in sponges is a key mechanism of penile erection. Therefore, Μ.Η.PAA improves male sexual function The effect can be explained by another mechanism that has not been fully understood. Finally, in the azimuth tracing gun about the complete picture of Μ.Η.PAA, it has excellent safety and tolerability compared with the currently known drug orange. Represents an important advantage. For example, in acute, subchronic, and narcotic studies conducted with rodents, rabbits, ghost dogs, and monkeys, It is toxic to the drug. In addition, it has neither any mutagenic effect nor induced effect in rabbits or mice. Rats who took M. Η · PAA for more than two generations did not have a fetal flu, Nor does it affect Zhan's reproductive activity. Finally, a 24-month carcinogenicity study on mice also showed that MHPAA has no toxicity and carcinogenic effects. Short-term and long-term clinical trials also show that this treatment is extremely complete and well tolerated The Ministry of Economic Affairs Central Liang Junfang 8 Workers' Consumer Cooperative Society ® The purpose of the present invention will be described in detail in the following examples. These examples will not limit the scope of the present invention. Example 1 Take 1000 grams of cracked sugarcane ® in 100- Melt at 110¾, add 200 grams of potassium vapor dissolved in 150 ml of water. Stir--17- This paper scale is applicable to China National Standard (CNS) A 4 specifications m〇X 2S7 mm) A6 B6 V. Invention This process is maintained for 5 hours under the description (). The solid agent is extracted from the solid obtained by this process for hours. The obtained extract is crystallized from it in room A. The alcohol complex in methyl ethyl chloride; the purity is 94.80 Between 5 and 82.5TC Μ. Η. PAA's table 4: the resulting Μ. Η. P. A component < please read the $ 面 之 注 + W-item then $ 本 买 > one-liquid extraction system uses heptane as the solvent Take Μ • Η • P • A • A * 1 2 cooling at temperature »Μ • Η • P • A • medium recrystallization 〇 to get up to 2 8 5 g 70% 〇 The mixture of the viscosity range is listed in Table 4 Lists the properties obtained by this method and the determination of the composition of the ft. The qualitative and fixed composition of each leave is 100%. Fermentation 1 _ twenty-six yards of fermentation 1-twenty-t alkane fermentation 1 octacosanol 1 _ twenty-nine yards of alcohol 1 triosyl alcohol 1 tris-decanol 1 tris-tetracosanol Example 2 This saponification process was carried out by wrapping 2 kg of crude sugar cane flats in 200 ml of water for 4 hours. Extract Μ.Η.P. 0.81 7.00 2.81 6 5.09 0.67 12.43 5.05 0.84 85-1001C with an atmosphere extraction system, add 00 grams of sodium hydroxide, and hold the imitation as a solvent under conventional solid-liquid extraction A with stirring A. For 10 hours, apply the obtained 18-paper size to the Chinese National Standard (CNS) A 4 specifications (210 X 297 g *) A6 B6 5. Description of the invention () The extract is cooled at room temperature. The solid solution is recrystallized in methanol, and finally recrystallized in an atmosphere / methyl ethyl ketone mixture. 405 grams of M.H.P.A.A. with a total purity of 92.5 2% was obtained. M.H.P.A.A.'s viscosity range is from 79.0 to 80.51 :: Table 5 lists the qualitative and fixed composition of M.H.P · A · A. Obtained by this method. Table 5: The qualitative and qualitative composition of the obtained M. Η. PA A. The percentage content of each alcohol (please read the precautions on the back first and then 9 ^ 本 1> _twenty four alcohol hexacosane Fermentation 0.87 6.84. 丨 installed. Printed by the Central Standard House of the Ministry of Economy and Economy βτ Gong Consumer Cooperative Society «3.08 6 2.92 0.80 12.66 4.65 0.70 1 -twenty-t-alkanol 1 1,2-octadecane fermentation 1 129-alkanol 1 _3 Decakanol 1-Thirty-two House Enzymes 1-Thirty-four Tetracane Enzymes Example 3 Add 1 2 kg of calcium hydroxide dissolved in 7 liters of water to 50 kg and refine it by melting under 100-1 20 in advance In sugarcane cricket. This saponification process is carried out with stirring for 7.5 hours. In the solid-liquid extraction system, ethyl yeast is used as a solvent to extract Μ.Η.PAΑ. 12 hours. The resulting extract is at room temperature Leave it to cool, and then recrystallize the solid plaque in an atmosphere. The purity of 93.77% is obtained. M. Η. PA Α. 13. -19- This paper scale is universal Chinese National Standard (CNS) A 4 specifications (210 X 297 mm) Order-A6 _B6_ V. Description of invention () 7 kg. The melting viscosity range of this mixture is 80. 0-82. 0C. Table 6 lists the Μ.Η.P obtained by this method . The qualitative and quantitative composition of AA. Table 6: The percentage content of each enzyme of the qualitative and quantitative composition of the obtained M. Η. PAA (please read the precautions on the back before filling this page) 1 Twenty-four Alcohol 0. 7 1 1 Hexadecanol 6. 8 8 1 Hexacosane fermentation 3. 0 6 1 octacosane fermentation 6 4. 7 0 1 _29-hexacosanol 0. 6 2 1 Triacosane yeast 12. 0 1 1 _ tridodecyl alcohol 5. 0 9 1 tritridecyl alcohol 0.70 Example 4 The hydrogenation of 8.6 kg dissolved in 4.5 liters of water Calcium added to 5 packs · Ordered-1 Printed by the R & C Consortium, Central Bureau of Standards, Ministry of Economic Affairs

千克預先在1 00 — 1 20TC熔化的粗制的甘蔗蟠中。皂 中過程在連缠攪拌下進行3小時。g固一液萃取器中用二 氛甲烷作溶劑萃取12小時。所得的産物冷却到室溫,得 到的固體在己烷和丙_ (1 : 1)混合物中重结晶。得到 純度為92. 91%的醇潺合物6. 8千克。Μ. Η. P .A. A.的熔點範圍為78. 5C-80. 5C。表7 列出了用此方法得到的Μ.Η. P.A.A.的定性和定 -20- 本紙張尺度適用中國國家標準(CNS)甲4规格(210 X 297公;ϊ ) 299230 A6 B6 五、發明説明() 量組成。 表7 ··所得Μ. Η. P. A. A.的定性和定量組成 组 分 各醇的百分含置 1 _二十四烷酵 1 一二十六院酵 1 一二十七烷醇 1 _二十八院酵 1 —二十九院酵 缦濟部中央標準房w工消费合作社印製 1 _三十烷酵 1 一三十二烷醇 1 _三十四烷酵 實施例5 向20千克預先在1 00_ 箱裂甘蔗蠟中加入稀釋在3 . 0 化鉀。皂化過程在建續攪拌下進 溶劑,在索氏萃取器中萃取M. 時。將萃取出的物質在室溫下冷 «仿(1 : 1)混合物中重结晶 % 的 Μ. Η. P. A. A. 3. .A.的熔黏範園在78. 5和 出了用此方法得到的Μ. Η. P 组成。 -2 Ι Ο . 7 . 3 . 6 3. 0 .12. 4 . 0 . 7 5 0 0 14 6 0 6 2 0 3 9 9 7 8 110C的溫度下熔化的 升水中的3. 7千克Ε氧 行5小時。用甲乙酮作為 H . P . A · A . 1 4 小 却。接著,將它在己烷/ ,得到純度為92. 56 8 千克。M . H . P . A 80. 5¾之間。表8列 .A. A.的定性與定量 (請先閲讀背面之注意事項再填寫本頁) 丨裝. 訂· 本紙張尺度逋用中a园家標準(CNS)甲4规格(210 X 297公釐) A6 B6 五、發明説明() 表8:所得Μ. Η. P.A.A.的定性和定量组成 组 分 各酵的百分含量 經濟部中央螵率局R工消費合作社印製 1 一二十四烷酵 1 _二十六烷酵 1 一二十七烷醇 1 一二十八烷酵 1 一二十九烷醇 1 一三十烷酵 1 一三十二烷酵 1 一三十四烷酵 實施例6 將250克氳氧化 克粗製甘蔗嫌中。此皂 在固一液萃取条统中用 .A . A . 1 2 小時。 重结晶。得到純度為9 .1 6 5 克。M . Η . 0 至 81. 5C。表 9 A. A.的定性和定量 表9 :所得M . Η . 组 分 0 6 3 6 3 0 12 5 0 8 5 5 6 10 10 7 2 18 3 1 7 4 鈣加到預先在1 OOt:熔化的1千 化過程在連埋攪拌下進行2小時》 2_丙醇作為溶劑萃取Μ.Η. Ρ 所得的産物在室溫下冷却,用庚烷 3. 63% 的 Μ. Η. P. A. A P.A. A.的熔黏範臞為80. 列出了用此法得到的Μ. Η. P. 组成。 P. A. Α.的定性和定置组成 各酵的百分含量 22 本纸張尺度適用中國國家標準(CNS)甲4规格(210 X 297公* ) (請先聞讀背面之注意事项再填寫拿頁) A6 B6 五、發明説明() 1 _二十四烷醇 1 _二十六焼醇 1 _二十iz院醇 1 —二十八烧酵 1 _二十九院酵 1 一三十烷酵 1 一三十二烷醇 1 _三十四烷醇 實施例7 將40 0克稀费在200¾升水 先在1 1 Ot:熔化的2千克精製甘蔗 續攪拌下保持3小時。在固鼷萃取器 取Μ. Η. P. A. Α. 6小時,用 重结晶。得到純度為95. 10%的 .389克。混合物的熔黏範圍為8 。表10列出了用此方法得到的Μ. 定性和定量组成。 表10:所得Μ. Η. P.A. Α. 組 分 0 . 6 . 3 . 6 4. 0 . 12. 4 . 0 . 8 4 5 2 18 13 6 9 5 4 9 3 8 0 中的氳氣化銷加到預 蟋中。這一過程在連 中用甲苯作為溶劑萃 甲醇作為溶劑第二次 Μ . Η . Ρ . A . A 1 . 0 至 8 3 · 0 ID Η · P . A . A .的 (請先閲讀背面之注意事项再填ί本買) 經濟部中央揉準渴貝工消费合作社印製 _二十四烷酵 —二十六烷酵 一二十t烷酵 的定性和定置组成 各醇的百分含置0.80 7.002.82 23- 本纸張尺度適用中國國家櫟準(CNS)甲4规格(210 X 297么、釐) 五、發明説明() A6 B6 (請先Μ讀背面之注項再蜞寫本頁> -丨裝. 訂· 經濟部中央標準扃霣工消费合作社印製 1 — 二 十 八 垸 酵 1 一 二 十 九 烷 酵 1 一 三 十 焼 醇 1 — 三 十 二 烷 酵 1 一 三 十 四 烷 酵 實 施 例 8 5 千 克 精 製 甘 0 毫 升 水 中 的 1 千 保 持 4 小 時 〇 在 固 • Η • Ρ • A • A » 用 甲 苯 作 為 溶 劑 度 為 9 2 • 2 0 % Μ • Η • Ρ * A • c 之 間 〇 表 1 1 列 * 的 定 性 與 定 量 组 表 1 1 所 得 Μ • 组 分 1 一 二 十 四 烷 醇 1 — 二 十 烷 醇 1 — 二 十 七 烷 醇 1 — 二 十 八 烷 醇 1 一 二 十 九 烷 醇Kilograms are pre-melted in crude sugarcane flats that melted at 100-120TC. The soap process is carried out for 3 hours with continuous stirring. In a solid-liquid extractor, dichloromethane was used as a solvent for 12 hours for extraction. The resulting product was cooled to room temperature, and the obtained solid was recrystallized in a mixture of hexane and propylene (1: 1). 8 kilograms of alcohol complex with a purity of 92.91% was obtained. 5C-80. 5C。 The melting point of Μ.Η.P.A.A. is 78. 5C-80. 5C. Table 7 lists the qualitative and qualitative -20 of Μ.Η.PAA obtained by this method- This paper scale is applicable to the Chinese National Standard (CNS) A4 specifications (210 X 297 g; ϊ) 299230 A6 B6 V. Description of the invention () Quantity composition. Table 7 ·· The obtained qualitative and quantitative composition of M. Η. PAA The percentage content of each alcohol 1 Home Enzyme 1 — Printed by the Central Standard House of the Ministry of Economy, Ministry of Economy, and Twenty-nine Homes, and printed by the Cooperative Consumer Cooperative 1 _ Thirty-Okane Enzyme 1 Tridecanol 1 _ Tridecane Enzyme Example 5 To 20 kg in advance in 1 00_ Box cracked sugar cane wax was added diluted with 3.0 potassium sulphate. During the saponification process, the solvent is added under continuous stirring, and M. is extracted in the Soxhlet extractor. The extracted material was recrystallized at room temperature in a cold «imitation (1: 1) mixture of% M.H. PAA 3. .A.'S melt-adhesive Fan Yuan at 78.5 and out of this method obtained Μ. Η. P composition. -2 Ι Ο. 7. 3. 6 3. 0. 12.4. 0. 7 5 0 0 14 6 0 6 2 0 3 9 9 7 8 3. 7 kg of E oxygen in molten water melted at a temperature of 110C 5 hours. Use methyl ethyl ketone as H. P. A. A. Next, place it in hexane / to obtain a purity of 92.56 8 kg. M. H. P. A 80. 5¾. Table 8 lists the qualitative and quantitative of AA (please read the precautions on the back and then fill out this page) 丨 installed. Ordered · This paper uses the Chinese Garden Standard (CNS) A 4 specifications (210 X 297 mm) A6 B6 V. Description of the invention () Table 8: The qualitative and quantitative composition of the obtained M. Η. PAA The percentage content of each leaven printed by the Ministry of Economic Affairs Central Bureau of Labor Development R Industrial and Consumer Cooperatives 1 Twenty-four four leaven 1 _ Hexadecanol fermentation 1 Hexadecanol 1 Benzoctane fermentation 1 Benzosalkyl alcohol 1 -30 octane fermentation 1 1-3 docane fermentation 1 1-3 decane fermentation Example 6 250 grams of oxidized grams of crude sugar cane were missed. This soap is used in solid-liquid extraction for .A. A. 12 hours. Recrystallization. The purity was 9.16 g. M. Η. 0 to 81.5 C. Table 9 Qualitative and quantitative of AA Table 9: The resulting M.H. component 0 6 3 6 3 0 12 5 0 8 5 5 6 10 10 7 2 18 3 1 7 4 Calcium was added in advance at 1 OOt: melted 1 Thousands of chemical processes were carried out under continuous agitation for 2 hours. 2_propanol was used as a solvent to extract M.Η.Ρ The resulting product was cooled at room temperature and melted with 3.63% M.Η.PA A PAA of heptane The sticky fan is 80. The composition of M.H.P. obtained by this method is listed. The qualitative and fixed composition of PA Α. The percentage content of each leaven is 22. The paper size is applicable to the Chinese National Standard (CNS) A 4 specifications (210 X 297 g *) (please read the precautions on the back and fill in the page) A6 B6 Fifth, the description of the invention () 1 _ Ticosanol 1 _ Twenty-six Alcohol 1 _ Twenty izuan alcohol 1 — Twenty-eight roasted yeast 1 _ Twenty-nine courtyard leaven 1 Thirty-thirane leaven 1 Tridecyl alcohol 1_tridecyl alcohol Example 7 400 g of dilute in 200¾ liters of water was first kept at 1 1 Ot: melted 2 kg of refined sugar cane for 3 hours with continued stirring. Take M.H.P.A.A. for 6 hours in a solid extractor and recrystallize it with. .389g with a purity of 95.10% was obtained. The melting range of the mixture is 8. Table 10 lists the qualitative and quantitative composition of M. obtained by this method. Table 10: Resulting M.H.PA Α. Components 0.6.3.6.4.0.12.4.0.8 4 5 2 18 13 6 9 5 4 9 3 8 0 Add to the pre-cricket. This process uses toluene as the solvent to extract methanol as the solvent for the second time. M.H.P.A.A 1.0 to 8 3 · 0 ID Η · P.A.A. (Please read the notes on the back first Please fill out the matter and buy again) Printed by the Central Ministry of Economic Affairs, quasi-thirsty Beigong Consumer Cooperative Co., Ltd. 7.002.82 23- This paper scale is applicable to China National Oak Quasi (CNS) A 4 specifications (210 X 297 ?, 5). Invention description () A6 B6 (Please read the notes on the back before writing this page >-Installed. Set · Printed by the Central Standards Department of the Ministry of Economic Affairs, Consumer Engineering Cooperative 1-28-Ester 1 Fermentation 1 29-Diastere Fermentation 1 Thirty-Third Alcohol 1-Tridodecane Enzyme 1 Thirty Tetrahydrolase Example 8 5 kg of purified sugar, 0,000 in 1 ml of water, kept for 4 hours. In solid • Η • Ρ • A • A »Using toluene as the solvent degree is 9 2 • 2 0% Μ • Η • Ρ * A • Between c ○ Table 1 1 column * Qualitative and quantitative groups Table 1 1 The obtained Μ • component 1 one-two-tetrakanol 1-two-barkanol 1-two-barcosane alcohol 1-two-barcosane alcohol 1 one-two-barcosane alcohol

簾 m 在 1 2 0 V 下 克 氫 氣 化 鉀 處 理 〇 一 液 萃 取 % 统 中 用 • 5 小 時 〇 然 後 » 將 Μ • Η • P • A 的 Μ • Η * P • A A • 的 熔 黏 範 圍 在 出 了 用 此 法 得 到 的 成 〇 Η Ρ A A 6 4.54 0.72 13.02 5.31 0.89 熔化後用稀箱在5 0 此過程在連績攪拌下 乙醇作為溶劑萃取Μ 将萃取液室溫下冷却 .A .结晶。得到砘 .A . 1 4 9 0 克。 7 9. 5 和 8 1 . 〇 Μ . Η . Ρ . A . A 的定性和定置组成 各醇的百分含霣 0.76 6.58 2.84 6 2.43 I0.71 -24- 本纸張尺度適用中國a家標準(CNS>甲4規格(210 X 297公* ) 經濟部中央櫺準局W工消费合作社印製 A6 B6 五、發明説明() 1一三十烷醇 13.08 1-三十二烷醇 5.05 1-三十四烷醇 0.75 實施例9 用 Μ • Η • P • A . A • 作 為 活 性 成 分 研製了 兩種 不 同 的 藥 物 裂 劑 • 其 成 分列在 表 1 2 中 〇 這 些 裂薄i是 考盧 了 活 性 成 分 的 物 理 、 化 學和物 理 化 學 特 黏 而 研 裂的。 用 濕 迪 粒 法 将 活 性组成 與 藥 物 賦 形 劑 按 照控制 的比 例 混 合 乾 燥 、 脱 粒 、 潤滑和 壓 錠 » 製 成 藥 爾 〇 表 1 2 用 Μ • Η • P . A A 作 為 活 性 成 分的藥 杨製 爾 組 分 裂 劑 1 製劑 2 ( % ) (% ) Μ • Η • P • A • A • 5 • 0 15. 0 乳 糖 5 6 0 5 4. 0 玉 米 澱 粉 1 5 0 10. 0 明 m 2 5 2 . 0 交 聯 的 羧 甲 基 m 維 素 纳 5 0 4 . 0 Μ 糖 5 0 4 . 0 滑 石 粉 2 0 2 . 0 硬 脂 酸 m 1 5 1 . 0 乙 醒 鄰 苯 二 甲 酸 纖 維 素 0 5 1 . 0 撖 晶 m 維 素 7 . 5 7 . 0 實例1 0 -25- 本紙張尺度通用中aa家標準(CNS)甲4規格(210 X 297公釐) (請先閲讀背面之注意事項再填寫本頁) -—裝_ 訂. A6 B6 五、發明説明() 使雄性紐西酺兔(2 — 3千克)適應實驗室條件15 天,隨機地分成4餹實驗组,一個對照組(只服用載劑) 和三籲Μ. Η. P. A. A.處理組。後三组成別用费管 飼法(1¾升/千克)分別服用懸浮在阿拉伯騵/水載爾 中的5、50和200毫克/千克的Μ. Η. P. A. A .4週。測定基線處的脂含量(開始治療前和治療4周後 )。在30天内口服5、 50、 200毫克/千克的M. Η. P. A. A.以一種舆劑置有囫的方式顯著的減少( Wilcoxon P<0.05) 總88固醇和血清中低密度蛋白的含置 。另外,對照組和處理组中百分數的受化统計學上是有差 異的(Mann Whitney U, P<0./05) •見画 1 - 4。在逭 一S驗条统中,服用最高劑量的Μ. Η. P. A.A.( 200毫克/千克)將血淸腔固酵和LDL-C分別降诉 5 1 — 78%。在所有四组中HDL-C含量均無明顯受 化(圔5)。比較處理组與對照組之間的甘油三酯百分含 量,受化也很明顯(Mann Whitney ϋ,Ρ<0.05),但未觀 察到劑量與效果間的顔偽(見圈6和7)。 實施例1 1 經 濟 部 中 央 標 準. M, 工 消 费 合 作 社 印 製 (請先閲讀背面之注意事项再填寫本買) 將雄性紐西蘭家兔隨機地分成4组:一掴對照组(只 用胃管飼法服用載劑)和分別用5毫升/千克Μ. Η. Ρ .A. Α·、二十八烷醇和二十六烷酵處理的3傾组。在 基線處和處理30天後測定血脂分佈。Μ. Η. Ρ. Α. Α.顯著降低總86固醇和LDL — C。另外,用Μ. Η. -2 6 - 本纸張尺度適用中國國家標準(CNS)甲4规格(210 X 297公釐) A6 _^_B6_ 五、發明説明() P. A. A.處理的家鬼的雎固酵、LDL-C和甘油三 脂比對照組的明顯降低。但是,在用二十八烷酵或二十六 烷醇處理的二组血脂的受化沒有统計學意義,结果見表1 3。 表13 :Μ. Η. P. A. A.、二十八烷酵和二十六烷 酵對血胺固酵正常的新西 家兔血脂含量(毫摩 爾/升)的影鬱 劑 量 组 別 (毫克/千克) 基 線 處理後 總胶固醇 (請先閲讀背面之注意事項再填窝本頁> —裝_ 經濟部中央標準局S工消費合作社印製 對 照 0 2 . 5 2 . 3 M.H.P.A. A. 5 2 . 8 1 . 6 * + 二十八烷醇 5 2 · 7 2 . 2 二十六烷酵 5 2 . 6 2 . 4 L D L - C 對 照 0 1 . 5 1 . 2 M . H . P . A . A . 5 1 . 3 0 . 6 # + 二十八烷酵 5 1 . 4 0 . 9 二十六烷酵 5 1 . 5 1 . 0 甘油三酯 -27- 訂· 本紙張尺度適用中國國家標準(CNS)甲4规格(210 X 297公釐) 五、發明説明() A6 B6 經濟部中兴標準居β:工消费合作社印製 對 照 0 0 • 8 0 0 * 8 2 Μ . H. P. A · A · 5 0 « 7 8 0 • 5 5 二 十 八 院 酵 5 0 • 7 7 0 • 7 0 二 十 烷 酵 5 0 • 8 0 0 » 7 8 #ρ < 0 .05 與 對 照 组 比 較 ( Mann whitney -U 檢 驗 ) < 0 .05 與 基 線 比 較 (Wile 0 X on) 實 施 例 1 2 在 僅 用 規 定 腊 食 5 周 之 後 • 4 5 名 膽 固 醇 值 和 L D L — C 值 用 食 物 不 足 以 控 制 的 門 診 病人 服 用 5 毫 克 Μ Η • P • A • A • 的 錠 劑 ( 毎 天 午 餐 和晩 餐 時 各 — 次 ) 或 無 效 對 照 剤 共 6 周 〇 在 這 段 有 效 治 療 期間 » 保 持 規 定 的 飲 食 條 件 〇 在 基 線 處 ( 只 服 規 定 飲 食 期 間結 束 時 ) 以 及 治 療 4 和 6 周 後 測 定 脂 含 量 〇 Μ • Η 暑 P .A • A • 將 總 血 淸 臛 固 醇 和 L D L — C 分 別 顯 著 地 降 低 16 • 2 3 % 和 2 1 • 3 3 % 〇 臛 固 醇 與 Η D L — C 的 比 和L D L — C 與 Η D L — C 之 比 ft 分 別 被 明 顯 地 減 少 1 1 .6 7 % 和 2 2 » 2 8 % ( P < 0 • 0 5 » 配 對 數 據 的 Wilcox ο η檢 驗 ) 〇 在 所 有 的 病 人 中 > 结 胺 固 醇 含 量 和 L D L -C 含 置 在 治 療 6 周 後 都 低 於 基 線 值 〇 其 它 脂 頚 组 成 含 量 的變 化 不 明 顦 » 結 果 列 在 表 1 4 和 1 5 中 〇 表 1 4 Μ • Η • Ρ • A • A • (1 0 牽 克 / 天 > 分 2 次 9 毎 次 5 毫 克 ) 對 患 I 型血 脂 蛋 白 過 多 病 人 血 淸 脂 分 布 ( 毫 莫 耳 / 升 ) 的影 *28- -----------------^-------裝------訂------^ 先閩3面之注$项再f本荑) 本纸張尺度適用中國國家標準(CNS)甲4规格(210 X 297公釐) A6 B6 經濟部中央揉毕局R工消费合作社印製 η 基線 6 周 (X + S D ) (X + S D ) 總膝固醇 M.H.P.A. Α. 22 7.43+1.29 6.21+1.38### 無效剤 23 6.97+0.72 6 . 7 0 + 0 . 75# L D L - C K.H.P.A. A . 22 5.54+1.22 4.35 + 1.3 1#*# 無效劑 23 5.07+0.63 4.97+0.67 L D L - C M.H.P. A. k . 22 1.03+0.26 1.10+0.28 無效剤 23 1.13+0.31 1.02+0.28 甘油三酯 M.H.P. A. A . 22 2.41+0.94 1.74+0.88 無效劑 23 2.03+0.64 1.87+0.67 V L D L -C M.H.P.A. A . 22 1.09+0.43 0.79+0.40 無效劑 23 0.92+0.29 0.85+0.31 一 η患者 數目 -29- (請先閲讀背面之注意事項再填寫本頁) 本纸張尺度適用中國國家標準(CNS)甲4规格(210 X 297 "K釐〉 經濟部中央檫準局R工消费合作社印製 A6 _B6_ 五、發明説明() -*Ρ<0.01; ***Ρ<〇.〇〇〇1,與基線比較(Wilcoxon) -a P<0.05與無效劑比較,绝對值,Mann Whitney U檢驗。 P<0.001 與無效劑比較,(Mann Whitney ϋ 檢驗)。 -”””Ρ< 0 . 0 0 0 0 1 與無效劑比較,(Kann Whitney U 檢驗)〇 表 15:M.H.P.A.A. (10毫克 / 天,分 2 次 每次5亮克)對患I型血脂蛋白過病人血淸脂比 率(毫莫耳/升)的影鬱 η 基線 6 周 (X+SD) ( X + S D )The curtain m is treated with potassium hydroxide at 120 V. One-liquid extraction is used for 5 hours. Then, the melt adhesion range of Μ • Η • P • A Μ • Η * P • AA • is in the range of In this way, the obtained ΗΗΡ AA 6 4.54 0.72 13.02 5.31 0.89 was melted and diluted with a thin box at 50. This process was followed by ethanol extraction with continuous stirring. The extract was cooled at room temperature. A. Crystallization. Get 磘 .A. 1 4 9 0 grams. 7 9. 5 and 8 1. 〇Μ. Η. Ρ. A. A qualitative and fixed composition of the percentage of each alcohol containing 霣 0.76 6.58 2.84 6 2.43 I0.71 -24- This paper scale is applicable to a Chinese standard (CNS > A4 specifications (210 X 297 g *)) A6 B6 printed by Wong Wong Consumer Cooperative of the Central Bureau of Economic Development of the Ministry of Economy V. Description of invention () 1 Triacontanol 13.08 1-Tridecanol 5.05 1- Tridecyl alcohol 0.75 Example 9 Two different drug splitting agents were developed with M • H • P • A • A • as active ingredients • The ingredients are listed in Table 1 2 These cracks are i The physical, chemical and physicochemical characteristics of the active ingredients are very sticky and cracked. The active ingredient and the pharmaceutical excipients are mixed in a controlled ratio by the wet dip method to dry, thresh, lubricate and press the tablet A medicine-based Yangschel group splitting agent 1 with Μ • Η • P. AA as preparation 2 (%) (%) Μ • Η • P • A • A • 5 • 0 15. 0 lactose 5 6 0 5 4. 0 Corn starch 1 5 0 10. 0 Ming m 2 5 2. 0 Cross-linked carboxymethyl m Vesuna 5 0 4. 0 Μ Sugar 5 0 4. 0 Talc 2 0 2. 0 Stearic acid m 1 5 1. 0 Cellulose ethoxylate phthalate 0 5 1. 0 Nanocrystalline m Vitamins 7. 5 7. 0 Example 1 0 -25- This paper standard is aa standard (CNS ) A4 specifications (210 X 297 mm) (please read the precautions on the back before filling in this page)--_ _ order. A6 B6 5. Description of the invention () Make male New Zealand rabbit (2-3 kg) Adapted to laboratory conditions for 15 days, randomly divided into 4 experimental groups, a control group (only taking the vehicle) and Sanyu M.Η.PAA treatment group. The latter three components were separately administered by fee tube feeding (1¾ litre / kg) for 5, 50, and 200 mg / kg of M.H.P.A.A. suspended for 4 weeks. Measure the lipid content at baseline (before starting treatment and after 4 weeks of treatment). The oral administration of 5, 50, and 200 mg / kg of M.H.P.A.A. within 30 days was significantly reduced in a manner in which a drug was placed (Wilcoxon P < 0.05). The content of total 88 sterols and low-density protein in serum. In addition, the percentage change in the control group and the treatment group is statistically different (Mann Whitney U, P < 0./05) • See pictures 1-4. In the Yi-S test system, the highest dose of M.H.P.A.A. (200 mg / kg) was used to reduce blood cavity solid fermentation and LDL-C to 5 1-78%, respectively. The HDL-C content was not significantly affected in all four groups (圔 5). Comparing the percentage of triglycerides between the treatment group and the control group, the effect was also obvious (Mann Whitney ϋ, Ρ < 0.05), but no falsehood between the dose and the effect was observed (see circles 6 and 7). Example 1 1 Central Standard of the Ministry of Economic Affairs. M, Printed by the Industrial and Consumer Cooperatives (please read the precautions on the back before filling in the purchase) The male New Zealand rabbits are randomly divided into 4 groups: a slap control group (stomach only Tube feeding method) and the 3-dip group treated with 5 ml / kg M.H.P.A.A., octacosanol and hexacosanol respectively. Blood lipid distribution was measured at baseline and after 30 days of treatment. Μ. Η. Ρ. Α. Α. Significantly reduced total 86 sterols and LDL-C. In addition, Μ. Η. -2 6-This paper scale is applicable to the Chinese National Standard (CNS) A 4 specifications (210 X 297 mm) A6 _ ^ _ B6_ V. Description of invention () PAA treatment of household ghosts Fermentation, LDL-C and triglycerides were significantly lower than the control group. However, there was no statistically significant effect on blood lipid in the two groups treated with octacosanol or hexacosanol. The results are shown in Table 13. Table 13: Shadow depression dosage groups (mg / kg) of PAH, octacosane fermentation and hexacosane fermentation on the serum lipid content (millimoles / liter) of normal western rabbits Total sterols after baseline treatment (please read the precautions on the back before filling the nest page) — — _ Printed by the Central Bureau of Standards of the Ministry of Economic Affairs, Printed by SIC Consumer Co., Ltd. 0 2. 5 2. 3 MHPAA 5 2. 8 1 6 * + octacosanol 5 2 · 7 2. 2 hexacosanol 5 2. 6 2. 4 LDL-C control 0 1. 5 1. 2 M. H. P. A. A. 5 1. 3 0. 6 # + octacosane fermentation 5 1. 4 0. 9 hexacosane fermentation 5 1. 5 1. 0 triglyceride-27- Order · This paper scale is applicable to China National Standards (CNS) A4 specifications (210 X 297 mm) V. Description of invention () A6 B6 ZTE Standard Residence of the Ministry of Economy β: Printed by the Industrial and Consumer Cooperatives 0 0 • 8 0 0 * 8 2 Μ. HP A · A · 5 0 « 7 8 0 • 5 5 Twenty-eight Hospitals leaven 5 0 • 7 7 0 • 7 0 Eicosanol leaven 5 0 • 8 0 0 »7 8 # ρ < 0 .05 Compared with the control group (Ma nn whitney -U test) < 0 .05 compared with baseline (Wile 0 X on) Example 1 2 After 5 weeks of using only prescribed foods • 45 cholesterol and LDL — C values are not adequately controlled with food Outpatients took 5 mg of Η Η • P • A • A • lozenges (each time for lunch and dinner) or ineffective controls for a total of 6 weeks. During this effective treatment period »Maintain the prescribed dietary conditions. At baseline (at the end of the prescribed diet period only) and after 4 and 6 weeks of treatment, the lipid content was determined. Μ • Η summer P .A • A • significantly reduced total blood ligustritol and LDL — C, respectively 16 • 2 3 % And 2 1 • 3 3% The ratio of lintosterol to Η DL — C and the ratio of LDL — C to Η DL — C ft were significantly reduced by 1 1.6 7% and 2 2 »2 8% ( P < 0 • 0 5 »Wilcox ο η test of paired data) 〇In all patients> Glucosamine Alcohol content and LDL-C content are lower than the baseline value after 6 weeks of treatment. The composition of other lipid corpuscles is unknown. The results are listed in Tables 1 4 and 1 5. Table 1 4 Μ • Η • Ρ • A • A • (10 0 g / day> 2 times 9 times each time 5 mg) on the distribution of blood lipid (millimol / liter) in patients with type I hyperlipoproteinemia * 28- ----- ------------ ^ ------- installed ------ ordered ------ ^ first three sides of the note $ item then f this book) this paper The Zhang scale applies the Chinese National Standard (CNS) A4 specifications (210 X 297 mm) A6 B6 Printed by the Central Bureau of Economic Development R Industrial and Consumer Cooperatives η Baseline 6 weeks (X + SD) (X + SD) Total knee strength Alcohol MHPA Α. 22 7.43 + 1.29 6.21 + 1.38 ### Invalidation 23 6.97 + 0.72 6 .7 0 + 0 .75 # LDL-C KHPA A. 22 5.54 + 1.22 4.35 + 1.3 1 # * # Ineffective agent 23 5.07 +0.63 4.97 + 0.67 LDL-C MHPA k. 22 1.03 + 0.26 1.10 + 0.28 Invalid 23 23 1.13 + 0.31 1.02 + 0.28 Triglyceride MHPA A. 22 2.41 + 0.94 1.7 4 + 0.88 Ineffective agent 23 2.03 + 0.64 1.87 + 0.67 VLDL -C MHPA A. 22 1.09 + 0.43 0.79 + 0.40 Ineffective agent 23 0.92 + 0.29 0.85 + 0.31 Number of patients -29- (Please read the notes on the back first (Fill in this page) This paper scale is applicable to the Chinese National Standard (CNS) Grade 4 (210 X 297 " K%> A6 _B6_ printed by the R and Consumer Cooperative Society of the Central Sassafras Bureau of the Ministry of Economic Affairs. 5. Description of the invention ()-* Ρ & lt 0.01; *** Ρ < 〇〇〇〇1, compared with the baseline (Wilcoxon)-a P < 0.05 compared with the ineffective agent, absolute value, Mann Whitney U test. P < 0.001 compared with ineffective agent (Mann Whitney ϋ test). -"" "P < 0. 0 0 0 0 1 compared with the ineffective agent, (Kann Whitney U test). Table 15: MHPAA (10 mg / day, divided into 2 times 5 liang each time) for patients with type I blood lipoprotein Shadow depression after the patient's blood lipid ratio (millimol / liter) η Baseline 6 weeks (X + SD) (X + SD)

LCL-C/HDL-C M.H.P.A.A. 22 5.71+1.82 4. 18+1.59** 無效劑 23 4.92+1.85 5.30+1.79 胺固醇/HDL-C M.H.P.A.A. 22 7.65+2.18 5.94+1.81*" 無效劑 23 6.69+2.21 7.06+2.05 -«Ρ<0.05 ; ##P<0.01, 與基線比較 (Wilcoxon) -a Ρ<0.05與無效劑比較,绝對值,Mann Whitney ϋ檢驗。 Ρ<0·05 與無效劑比較,(Mann Whitney U 檢驗)。 一 ’’’’p<〇.01 與無效劑比較,(Mann Whitney II 檢驗)。 實施例1 3 一组患Π型血脂蛋白過多症的病人在8周僅食用規定 -3 0 - 本纸張尺度適用中國a家標準(CNS)甲4规格(210 X 297公釐) -----------------_------裝------訂 (請先閲面之注意事項再填寫本買> A6 B6 五、發明説明() 經濟部中央樣準局R工消费合作社印製 飲 食 後 ( 基 線 ), 服 甩 含1 5 毫 克 组 合 物 的 錠劑 〇 在 基 線 處 和 在 治 療 8 周後 测 定 血脂 分 布 〇 主 要 結 果 绝結 在 表 1 6 Φ 〇 含 有 Μ • Η . Ρ • A . A • 的 製 劑 將 血 淸總 貼 酵 顯 著 地 降 低 1 6 • 4 4 % , L D L — C 降 低 2 3 .5 1 % ( 見 圖 8 ) 0 Η D L - C 增 加6 • 4 0 % » 而 甘 油三 酯 和 棰 低 密 度 脂 蛋 白臛 固 醇 (V L D L — C ) 分 別減 少 7 • 8 0 % 和 1 0 • 8 3 % » 但是 這 些 變 化 在 統 計 學上 不 頭 著 〇 表 1 7 中 列 出 了 L D C -C 與 Η D L — C 之 比和 膝 固 酵 與 Η D L — C 之 比的 受 化 ,它 們 分 別 顯 著 地 減 少了 2 9 » 0 7 % 和 2 3 • 7 2 % 〇 表 1 6 = Μ • Η . Ρ • A . A • 對 患 者 I 型 血脂 血 脂 蛋 白 過 多 的病 人 血 涫脂 分 布 和 脂 蛋 白 的 彩鬱 參 量 η 基線 η 6 周 ( X + S D ) ( X + S D ) 膝 固 酵 25 7 .84 + 1. 14 25 6 .50 + 1. 2 1 L D L — C 17 5 .86 + 1 · 11 18 4 .33 + 1. 32 4 # Η D L — C 19 1 .03 + 0 . 44 20 1 .21+0. 46 甘 油 三 酯 19 2 .3 0 + 1. 42 20 2 .14+1. 06 V L D L — C 19 1 .05 + 0 . 64 20 0 .97 + 0 . 48 #«Ρ<0. 01 < 〇· 0001 (Wile 0 X on檢 驗 ) 表 1 7 ·· Μ . Η • P . A * A • 對 患 I 型血 脂 蛋 白 過 高的 病 人 L D L — C / Η D L -C 和 胺 固 酵 / Η D L -C 比 值 的 影 響 -31- (請先聞讀背面之注4m·项再填寫本頁) 本紙張尺度通用中國國家標準(CNS)甲4规格(210 X 297公釐〉 299230 A6 __B6_ 五、發明説明() (請先聞讀背面之注f項再填寫本頁) 參數 η 基線 η 8 爵 (X + S D ) LDL-C/HDL-C 17 6.34+2.79 18 3.82+1.55*« 臛固醇 /HDL-C 19 8.83 + 3.49 20 6 . 07 + 2 . 17#* * * Ρ < 0 . 0 1 (If i 1 c ο X ο η 檢驗) 實施例1 4 首先,研究Η. P. A. Α.的作用和它對胨苷二磷酸 (ADP)和匾原誘發的大鼠小板聚集的彩«。將一群重 2 5 0至3 5 0克的雄性Sprague-Dae ley大E随機地分成 兩偭實驗组。用费飼管口服Μ. Η. P. A. A.在阿拉 伯醪一水載劑的懸浮液4周。2组中一個是只服用載劑的 對照组,另一組則用Μ. H . P. A. Α.處理(25¾ 克/千克)。為進行血小板聚集的鑑定,將大鼠在乙醚氣 氛中麻醉。打開腹部由腔靜脈抽血5毫升,與3. 8%的 級濟部中央揉準居员工消费合作社印製 掙橛酸鈉混合(毎9體積血用1體積的檸檬酸)。將血液 雔心,得到富含血小板的血漿(PRP)。將PRP液在 330xg下離心15分鐘,得到撖置血小板的血漿(P PP) ^用腺苷二磷酸和匾原誘發此小板聚集,用一台 Payton 集合度計按文獻所述進行測定(McGregor 1., Horanzain R.和 Renaud S.;1980;食用亞油酸對大鼠血小 板功能的影播;Thraabosis Res.20.499)。用非參數的 Hann-Whitney U檢驗比較治療組與對照組之間的结果。用 25€克/千克的Μ. Η. P. A. A.治療4週的大鼠 -32- 本纸張尺度適用中國國家標準(CNS)甲4規格(210 X 297公釐) 设濟部中央標準局R工消費合作社印製 A6 _^_B6_ 五、發明説明() ,在服用次高劑量的腺苷二碟酸和謬原時,顯著地抑制了 臞外血小板的聚集(見画9和10)。大鼠口服Μ. H. P. A.A.四周顔著抑裂腺苷二磷酸和睡原誘發的血小 板聚集谊一事實,說明M.H. P. A. A.作為抗血小 板藥物起作用。 實施例1 5 為了檢驗Μ. Η. P. A. A.對大鼠體外血小板聚 集的影留,進行了它的抗血小板聚集作用時間過程的研究 。為此,將重2 5 0至3 5 0克的兩種性別的5?^塞118·LCL-C / HDL-C MHPAA 22 5.71 + 1.82 4. 18 + 1.59 ** Ineffective agent 23 4.92 + 1.85 5.30 + 1.79 Aminosterol / HDL-C MHPAA 22 7.65 + 2.18 5.94 + 1.81 * " Ineffective agent 23 6.69 +2.21 7.06 + 2.05-«Ρ <0.05;## P < 0.01, compared with baseline (Wilcoxon) -a Ρ &0.05; compared with ineffective agent, absolute value, Mann Whitney ϋ test. Ρ < 0.05 compared with ineffective agents (Mann Whitney U test). 1. ‘’ ’p < 〇.01 compared with the ineffective agent (Mann Whitney II test). Example 1 3 A group of patients with type Ⅱ hyperlipoproteinemia should only consume at 8 weeks -3 0-This paper scale is applicable to the Chinese a standard (CNS) A4 specification (210 X 297 mm) --- --------------_------ installed ------ ordered (please read the precautions first and then fill in the purchase) A6 B6 V. Invention description ( ) After printing the diet (baseline) of the Ronggong Consumer Cooperative of the Central Bureau of Samples of the Ministry of Economic Affairs, take a lozenge containing 15 mg of the composition. Measure the blood lipid distribution at the baseline and after 8 weeks of treatment. The main results are summarized in the table. 1 6 Φ 〇 The preparations containing Μ • Η. Ρ • A. A • significantly reduced the total amount of blood fermented by 16 4 4%, and the LDL — C decreased by 2 3 5 1% (see FIG. 8) 0 Η DL-C increased by 6 • 4 0% »while triglycerides and low-density lipoprotein linsterol (VLDL — C) decreased by 7 • 8 0% and 1 0 • 8 3%» but these changes were statistically Nothing. Table 17 lists the ratio of LDC -C to Η DL — C and the ratio of knee solid yeast to Η DL — C Subject to chemical, they significantly reduced 2 9 »0 7% and 2 3 • 7 2% 〇 Table 16 = Μ • Η. Ρ • A. A • For patients with type I blood lipid hyperlipoproteinemia patients with blood sputum Distribution and parameters of lipoprotein color depression η Baseline η 6 weeks (X + SD) (X + SD) Knee solid yeast 25 7 .84 + 1. 14 25 6 .50 + 1. 2 1 LDL — C 17 5 .86 + 1 · 11 18 4 .33 + 1. 32 4 # Η DL — C 19 1 .03 + 0. 44 20 1 .21 + 0. 46 triglycerides 19 2 .3 0 + 1. 42 20 2 .14 +1. 06 VLDL — C 19 1 .05 + 0. 64 20 0 .97 + 0. 48 # «Ρ < 0. 01 < 〇. 0001 (Wile 0 X on test) Table 1 7 ·· Μ. Η • P. A * A • Effects on the ratio of LDL — C / Η DL -C and amine-solid enzyme / Η DL -C in patients with type I hyperlipoprotein -31- (please read note 4m on the back first (Enter this page again) This paper standard is universal Chinese National Standard (CNS) A 4 specifications (210 X 297 mm) 299230 A 6 __B6_ V. Description of invention () (please read note f on the back and then fill in this page) Parameter η Baseline η 8 Sir (X + SD) LDL-C / HDL-C 17 6.34 + 2.79 18 3.82 + 1.55 * «Holsterol / HDL-C 19 8.83 + 3.49 20 6. 07 + 2. 17 # * * * Ρ < 0. 0 1 (If i 1 c ο X ο η test) Example 1 4 First, study Η . The role of PA Α. And its effect on peptone diphosphate (ADP) and plaque-induced rat platelet aggregation «. A group of male Sprague-Dae ley Big E weighing 2 50 to 350 grams were randomly divided into two experimental groups. A suspension of M.H.P.A.A. in Arab mash mono-water vehicle was orally administered with a fee-feeding tube for 4 weeks. One of the two groups was a control group that only took the vehicle, and the other group was treated with M.H.P.A.A. (25¾ g / kg). For identification of platelet aggregation, rats were anesthetized in ether atmosphere. Open the abdomen and draw 5 ml of blood from the vena cava, mixed with 3.8% grade Jibu Central Kneading Zhunju Employee Consumer Cooperative Printed Sodium Prongate (mixed with 9 volumes of blood and 1 volume of citric acid). Carry the blood into the heart to obtain platelet-rich plasma (PRP). The PRP solution was centrifuged at 330xg for 15 minutes to obtain platelet-containing plasma (P PP) ^ This platelet was induced to aggregate with adenosine diphosphate and plaque, and was measured using a Payton concentration meter as described in the literature (McGregor 1., Horanzain R. and Renaud S .; 1980; Effect of edible linoleic acid on platelet function in rats; Thraabosis Res. 20.499). The nonparametric Hann-Whitney U test was used to compare the results between the treatment group and the control group. Rats treated with Μ.Η.PAA of 25 € g / kg for 4 weeks-32- This paper scale is applicable to the Chinese National Standard (CNS) A4 specifications (210 X 297 mm). A6 _ ^ _ B6_ printed by the consumer cooperative. 5. Description of the invention (). When taking the next highest dose of adenosine didiscate and erogen, it significantly inhibited the aggregation of extraplatelets (see pictures 9 and 10). The fact that M. H. P. A. A. was surrounded by anti-crack adenosine diphosphate and sleep platelet-induced platelet aggregation in rats showed that M. H. P. A. A. functions as an anti-platelet drug. Example 15 In order to examine the effect of M.H.P.A.A. on platelet aggregation in vitro of rats, the time course of its antiplatelet aggregation action was studied. To this end, will the weight of 2 5 0 to 3 50 grams of two genders 5? ^ 118

Da vi ley大鼠分成四個組:一儸對照组和三傾分別用單劑置 為 25、50、和 200¾克/千克Μ, Η. P. A. A .處置的實驗组。另外,在服用200奄克/千克的1!置 2、6和24小時之後,研究對血小板聚集的影鬱。M. Η. P. A. A.用實施例14中所述的方法製備,以一 次劑量的形式在實驗前2小時口服給藥。對照的動物服用 相同鱷稹的載劑,所有的動物均禁食,但是在實驗前20 小時自由飲水。用乙醚將所有的動物麻醉,從腔靜脈抽血 ,與3. 8%的檸樣酸鈉惹合(毎9鳢稱血液加1鳢積抗 凝血劑)。將血在250s離心10分鐘以得到富含血小 板的血漿(PRP)。一旦分離出PRP,將剩餘的部分 在1 300g離心15分鐘,得到微置血小板的血漿(P PP)。用濁度法定量拥定血小板聚集度(Born, G., 1 9 6 2 ;腺苷二酸引起的血小板聚集及其分解;Nature -33- 本紙張尺度適用中國國家標準(CNS〉甲4规格(210 X 297公«·) (請先閲讀背面之注意事項再填寫本頁) •丨裝. 訂· 經濟部中央標準局R工消费合作社印货 A6 ___B6_ 五、發明説明() (London) 1 9 4 , 9 2 7 - 9 2 9)。將儀器較正為對RPP透光率 為0%、對PPP為100%,然後測定血小板聚集度。 記錄聚集曲線5分鐘。結杲用大量聚集百分數(%)表示 。各组之間用 Wann-Whitney U檢驗(P<<0.05)比較。在 採血樣前2小時服用Μ. Η. P. A. A. (50和20 0¾克/千克)抑制了腺苷二碟酸誘發的血小板聚集,而 較低的劑置(25毫克/千克)沒有明顯改變對腺苷二联 酸的堪應(見圖1 1)。蓮擇最高劑置的Μ. Η· Ρ· A .A. (200毫克/千克)研究抗血小板作用的時間過 程。雖然在2小時後血小板的聚被明顯地抑制,但是6小 時後這種抑制作用就愛成不很明顯(P = 0. 06),而 在24小時後已得不到统計學上有意義的结果(見圓12 )。结果表明,在採血2小時前讓大鼠口服多二十烷酵, 在用50和200¾克/千克的Μ. Η. P. A. A.處 置的大鼠的P R P中以與_量依賴的路傈抑制了腺苷二羁 酸誘發的血小板聚榘。Μ. Η. P. A. A·對腺苷二磅 酸誘發的聚集的抑制作用是可逆的,因為在用它以200 毫克/千克的劑量處理6小時後,#血小板聚集的抑制作 用已不很明顯,而在處理24小時後,觀察到效果喪失, 說明Μ. H.P. A. A.不會造成永久性的細胞變化。 實施例1 6 研究了Μ. Η. P.A. A.對大鼠髅内靜脈血小板 聚集的影鬱和對小鼠誘發的死亡率的影堪。將重250至 -34- (請先H讀背面之注項再填寫*頁) —裝· 訂· <· 本紙張尺度通用中國國家標準(CNS)甲4规格(210 X 297 ¾¾) 經濟部中央櫺準居β工消费合作社印製 A6 ____B6_ 五、發明説明() 3 0 0克的Sprague Dawley雄大鼠和重2 0至2 5克的5 7BL6雌性小鼠隨機地分成幾實驗組。Μ. Η. P. A • A.按實施例14所述製備,乙醒水欏酸(ASA)貝!] 溶解在5%的NaCOs中。在鑑定前12小時用管飼法 口服藥物。在口服藥物16小時前動物禁食。雄大鼠按1 毫升/100克涯重、小雌鼠按0. 5毫升/20克鳢重Da vi ley rats were divided into four groups: the experimental group treated with a single dose of 25, 50, and 200 ¾ g / kg M, H.P. In addition, after taking 200 μg / kg of 1! For 2, 6 and 24 hours, the effect on platelet aggregation was studied. M.H.P.A.A. was prepared by the method described in Example 14, and was administered orally in a single dose 2 hours before the experiment. Control animals took the same crocodile carrier. All animals were fasted, but they were free to drink water 20 hours before the experiment. All animals were anesthetized with ether, blood was drawn from the vena cava and concomitant with 3.8% sodium citrate (each 9 snakeheads called blood plus 1 snakehead anticoagulant). The blood was centrifuged at 250 s for 10 minutes to obtain platelet-rich plasma (PRP). Once PRP is separated, the remaining portion is centrifuged at 1,300 g for 15 minutes to obtain platelet-free plasma (P PP). Quantitative determination of platelet aggregation degree by turbidity method (Born, G., 1 9 6 2; platelet aggregation and decomposition caused by adenosine diacid; Nature -33- This paper scale is applicable to China National Standard (CNS> A4 specifications (210 X 297 Gong «·) (Please read the precautions on the back before filling out this page) • Installed. Ordered · Printed by the Central Standards Bureau of the Ministry of Economic Affairs R & Consumer Cooperative A6 ___B6_ V. Description of invention () (London) 1 9 4, 9 2 7-9 2 9). Calibrate the instrument to 0% for RPP and 100% for PPP, and then determine the platelet aggregation degree. Record the aggregation curve for 5 minutes. Use a large percentage of aggregation ( %). The Wann-Whitney U test (P < < 0.05) was used for comparison among the groups. Taking M.H. PAA (50 and 200 g / kg) 2 hours before the blood sampling inhibited the adenosine disc. Acid-induced platelet aggregation, while the lower dose (25 mg / kg) did not significantly change the response to adenosine diacid (see Figure 11). The highest dose of L. .A. (200 mg / kg) to study the time course of the antiplatelet effect. Although platelet aggregation was significantly inhibited after 2 hours , But this inhibitory effect became less obvious after 6 hours (P = 0.06), and statistically meaningful results were not available after 24 hours (see circle 12). The results show that after blood collection 2 Hours ago, rats were given oral docosane fermentation. In rats treated with 50 and 200 ¾ g / kg of M.H.PAA, PRP treated with a dose-dependent pathway inhibited adenosine disulfate-induced Platelet aggregation. Μ.Η.PA A · inhibition of adenosine dipound acid-induced aggregation is reversible, because after treatment with it at a dose of 200 mg / kg for 6 hours, #platelet aggregation inhibition has been Not very obvious, but after 24 hours of treatment, the loss of effect was observed, indicating that M. HPAA does not cause permanent cell changes. Example 16 The effect of M. Η. PAA on platelet aggregation in rat venous veins was investigated Yuhe's impact on the mortality rate induced by mice. Will weigh 250 to -34- (please read the notes on the back first and then fill in the * page)-Pack · Order · < · This paper standard is universal Chinese national standard ( CNS) A 4 specifications (210 X 297 ¾¾) Ministry of Economic Affairs, Central Ministry of Housing and Industry, β-consumer cooperative System A6 ____B6_ V. Description of the invention () 300g Sprague Dawley male rats and 5 7BL6 female mice weighing 20 to 25g are randomly divided into several experimental groups. Μ. Η.P.A • A. according to Prepared as described in Example 14, acetoacetate (ASA) shellfish is dissolved in 5% NaCOs. The drug was taken orally by tube feeding 12 hours before identification. Animals were fasted 16 hours before oral medication. Male rats weigh 1 ml / 100 grams, and female rats weigh 0.5 ml / 20 grams.

服藥,按照動物則服用相當鱷積的載费I。在大竄的靜脈内 血小板聚集研究中使用四健實驗组:⑴對照组、⑵⑶⑷分 別服用5、 10和20¾克/千克的Μ. Η. P. A. A .。將動物用戊巴比妥納腹膜内麻醉(30_40毫克/ 千克)。在將3 0毫克/千克的醪原注射到陰莖脈中之前 和9 0秒之後,將一根套管控到項總動脈中採取血樣》在 含有0. 7¾克/毫升消炎痛和19毫克/毫升EDTA 的100撖升混合物的塑料管中收集900橄升血液。取 一部分通過光學潁撤鏡計數測定各樣品中的血小板S度。 然後將血液離心,血漿丙二醛(MDA)濃度通過硫巴比 妥酸法定量測定(Sat Qh , 1 9 78 ;測定腦血管障礙中血 脂過氣化物的新比色法;Clin Chim. Acta 90,34-43) 。注射膠原之後血小板計數和血漿MDA濃度的變化用基 線值的百分數表示。對照组和處理組之間的差異性用》41111-W b i t n e y 1]檢驗法確法。 為了研究膠原誘發的大鼠死亡率,將實驗分组如下: 1)對照组:動栩只服用載劑,但是用靜昵内注射膠原法 -35- 本纸張尺度適用中國國家標準(CNS)甲4规格(210 X 297公* ) <請先閲讀背面之注4m-项再填寫本頁) -裝. 订· 經濟部中央櫺準局貝工消费合作杜印製 A6 __B6_ 五、發明説明() 誘發死亡; 2) 在注射騮原2小前,用360毫克/千克醱重的M. Η. P. A.A.預先處理動物; 3) 在誘發死亡前1、4、8和24小時,用360毫克 /千克體重的Μ. Η. P. A. A.預先處理動物; 4) 在檢測前2小時,用180毫克/千克體重和Μ. Η .P. A. Α.和50¾克/千克體重的ASA對動 物預處理。 按文獻所述裂備II型酸溶的小牛皮膠原(Kieiura Y., Kaube T.和 Watanabe K., 1985; Celostagel 對血小板聚 集和實驗血检形成的影W ; ArzneiB Forsch Drug Res.35 ,114-1148 ),以最终瀝度為2. 5¾克/毫升使用。通 過眼眶後血管從注射,劑量為0.1毫升/20克髓重。 逭一劑量造成對照動饬60%至100%的死亡率。對照 動物和處理過的動物之間死亡百分率的比較用Fixcher正 合概率檢驗法進行。 Μ. Η. P.A.A.明顯地抑制了由膠原誘發的循 環血小板計數的減少和血漿中MD A濃度的同時增加(見 圖13) 。360¾克/千克髏重的Μ. Η. P. A. A 使願原誘發的死亡率大大降低(見_1 4)。對膠致死的 逭種保護效果在檢測前1和4小時服用這一劑置時觀察到 的·但是在檢測前8小時服用則不顯著(見圖15)。 Μ . Η . Ρ . A . A . (180毫克/千克體重)和 -3 6 - (請先Μ讀背面之注意事項再頁) -裝- 訂. ,泉· 本纸張尺度適用中國a家標準(CNS)甲4规格(210 X 297公* ) 經濟部中央標準局貝工消费合作杜印製 A6 _B6_ 五、發明説明() ASA (50¾克/千克醱重)的结合應用也造成暖原致 死率在统計學意義上的顯著降低,而當二者單獨服用時均 無效果(見圈16)。箪獾服時無效的Μ. Η. P. A. A.爾置和八3六_量,在一起用時有明顴的保護作用, 從而表明Μ. Η. P. A.A.和ASA的抗血栓形成效 果有協同作用。 實施例1 7 為了分析Μ. Η. P.A.A.對大鼠大腦硬塞的影 轚,將匾重2 9 0至3 3 0克的Sprague Dawley雄嵐分成 以下實驗组: 1) 陽性對照組:未結紮的大鼠只用费管飼法服用載劑; 2) 陽性對照组:结紮的大鼠也用爾管飼法服用載劑; 3) 和4):結紮的大鼠用同樣的途徑分別服用Μ. H. P.A.A. (5和25毫克/千克鼸重 不同的治療组逐日服用4遇》最後一組如逭種棋型 中通常採用的情形,在結紮前12小時和结紮後8和24 小時服_。 為了誘發大腦局部缺血,將動0輕撤地麻醉,通過將 頸缌動昵雙倒结紮造成血置減少。緊接箸皮下注射硝普酸 鈉(0. 8毫克/250克髏重)以造成動脈低血E。6 0分鐘後取下頸動脲頭,觀察動物72小時,然後殺死。 迅速取出大腦,在80C的烘箱中放置24小時。測定濕 重和乾重以確定水含量(水臛),採用以下公式: -37- 本紙張尺度適用中國國家標準(CNS)甲4規格(210 X 297公釐) ----------------(--------裝------訂-----·(« (請先Η讀背面之注意事項再填寫本頁> A6 B6 後濟部中去標準房RX消費合作社印« 採用非參量的 析。逐曰服用2 5 A · 4周能顯著減 一劑置也減少了死 這兩項降低没有逹 5毫克/千克鱧重 鼠腦局部缺血有明 。所治療的動物中 ,但是逭一減小未 表 1 8 ·· Μ . Η . 的影響 五、發明説明( 漉重一乾重 水腫= 濕 重Take the medicine, according to the animal, take a considerable crocodile load I. The Sijian experimental group was used in the study of intravenous platelet aggregation in Dachan: ⑴ control group, ⑵⑶⑷, respectively, 5, 10 and 20¾ g / kg of M.H.P.A.A. Animals were anesthetized with pentobarbital (30_40 mg / kg). Before injecting 30 mg / kg of mash into the penile vein and after 90 seconds, a cannula was taken into the common artery to take a blood sample. "Including 0.73 g / ml indomethacin and 19 mg / ml Collect 900 olive liters of blood in a plastic tube of 100 litres of EDTA. Take a part to measure the platelet S level in each sample by counting with an optical microscope. The blood was then centrifuged, and the plasma malondialdehyde (MDA) concentration was quantitatively determined by the thiobarbituric acid method (Sat Qh, 1 9 78; new colorimetric method for the determination of blood lipid pergasification in cerebrovascular disorders; Clin Chim. Acta 90 , 34-43). The changes in platelet count and plasma MDA concentration after collagen injection are expressed as a percentage of the baseline value. The difference between the control group and the treatment group was confirmed by the "41111-W b i t n e y 1] test. In order to study the collagen-induced rat mortality, the experiments were divided into the following groups: 1) Control group: Dongxu only took the carrier, but the collagen injection method was used -35- This paper scale is applicable to the Chinese National Standard (CNS) A 4 Specifications (210 X 297 g *) < Please read the note 4m- item on the back first and then fill in this page)-Packing. Order · A6 __B6_ Printed by the Ministry of Economic Affairs, Central Bureau of Industry and Economic Cooperation, V. Description of invention ( ) Induced death; 2) Pretreated animals with 360 mg / kg of M.H. PAA 2 hours before the injection of Kojihara; 3) 360 mg / 1, 4, 8 and 24 hours before induced death Kg body weight of M.H. PAA pre-treated animals; 4) 2 hours before the test, the animals were pretreated with 180 mg / kg body weight and M.H. PA A. and 50¾ g / kg body weight of ASA. Preparation of type II acid-soluble calf leather collagen as described in the literature (Kieiura Y., Kaube T. and Watanabe K., 1985; Celostagel's effects on platelet aggregation and experimental blood tests W; ArzneiB Forsch Drug Res. 35, 114 -1148), with a final leaching of 2.5 5g / ml. From the injection through the posterior orbital blood vessel, the dose is 0.1 ml / 20 g of pulp weight. One dose caused 60% to 100% mortality of the control animal. The comparison of the percentage of death between the control animals and the treated animals was performed using the Fixcher fit probability test. Μ.Η.P.A.A. obviously inhibited the decrease of circulating platelet count induced by collagen and the simultaneous increase of plasma MDA concentration (see Figure 13). M.H.P.A.A of 360¾ g / kg bone weight greatly reduces the mortality rate induced by the wishing (see _1 4). The lethal protection effect on gums was observed when this dose was taken 1 and 4 hours before the test, but it was not significant when taken 8 hours before the test (see Figure 15). Μ. Η. Ρ. A. A. (180 mg / kg body weight) and-3 6-(please read the precautions on the back page first)-Binding-Order., Quan · This paper size is suitable for a Chinese company Standard (CNS) A4 specification (210 X 297 g *) A6 _B6_ produced by the Beigong Consumer Cooperation of the Central Bureau of Standards of the Ministry of Economic Affairs V. Description of invention () The combined application of ASA (50¾ g / kg weight) also caused warming The lethality was statistically significantly reduced, but when both were taken alone, there was no effect (see circle 16). The M.H.P.A.A. Erzhi and the eight-thirty-six-quantity that were not effective when the badger was taken, had the protective effect of Mingzhi when used together, thus indicating that the antithrombotic effects of M.H.P.A.A. and ASA have a synergistic effect. Example 17 In order to analyze the effect of Μ.Η.PAA on rat cerebral embolism, Sprague Dawley male plaques weighing 2 9 0 to 3 30 grams were divided into the following experimental groups: 1) Positive control group: not ligated Of rats only took the carrier by the method of tube feeding; 2) positive control group: the ligated rats also took the carrier by the method of tube feeding; 3) and 4): the ligated rats took the same route separately. .HPAA (the treatment groups with different weights of 5 and 25 mg / kg mandarin weight are taken 4 times a day). The last group is as usual in the shape of the chessboard. It is taken 12 hours before the ligation and 8 and 24 hours after the ligation. Induce ischemia of the brain, anesthetize gently, and reduce the blood volume by ligating the neck and moving it. Inject the sodium nitroprusside (0.8 mg / 250 g bone weight) subcutaneously immediately Arterial hypotension E. Remove the cervical urea head after 60 minutes, observe the animal for 72 hours, and then kill it. Quickly remove the brain and place it in an oven at 80C for 24 hours. Determine the wet weight and dry weight to determine the water content (hydrazone) ), Using the following formula: -37- This paper scale is applicable to China National Standard (CNS) A4 specifications ( 210 X 297 mm) ---------------- (-------- install ------ order ----- · («(please first Η Read the precautions on the back and then fill out this page> A6 B6 After the Ministry of Economy, go to the standard room RX consumer cooperative print «A non-parametric analysis is used. Taking 2 5 A every day can significantly reduce the dosage of one dose and also reduce it. The two reductions in death are not as obvious as the cerebral ischemia of 5 mg / kg of snakehead rats. In the treated animals, but the effects of reduction are not shown in Table 18 ·· Μ. Η. Fifth, the description of the invention (漉 重One dry weight edema = wet weight

Mann-Whitney U檢驗對結果進行統計分 〇毫克/千克體重的Μ. Η. P. A. 輕大腦水腫(P<<0. 0. 5)。這 亡率和患水腫動物的百分數,雖然另外 到顯著的水平。這些發現表明,服用2 的Μ. Η. P. A. A.對實驗誘發的 頚的保護作用,因為大脑水腫大大減輕 顯示出大腦水腫面稹的百分數也有減小 達到顯著水平(見表18)。 P. A. A.對大與誘發性大腦性缺血 ----------------^--------裝------訂-----Z (請先Μ讀背面之注項再填窝本 劑 置 百 分 數 實驗組 (毫克/千克) 水腫 死亡 動物 (_ )對照 0 79.3+/-0.39 -- - - (+ )對照 0 80 . 1 + /-0.82 35 54.5 M . H . P . A . A . 5 80 .0 + /-0. 9 1 40 33.3 M.H.P.A.A. 25 79 . 5 + /- 0 .49# 28 7 . 6 (_ )對照: 陰性對照;( + )對照:陽性對照: X與陽 性對照相比差異明顯;P < < 0 . 〇 5 ( Mann-Whitney U - 38- 本紙張尺度適用中國國家標準(CNS)甲4规格(210 X 297公釐) A6 _ B6_ 五、發明説明() 檢驗)。 實施例1 8 為研究Μ. Η. P.A.A.和阿斯匹林對於誘發的 大鼠大腦缺血症的協同效應,將重250至300克的雄 性S p 1: a g u e D a η 1 e y鼠分成5组 1 )陰性對照(未结紮的鼠); 2) 陽性對照(只服用載劑的结紮的動物); 3) 管飼法口服25毫克/千克醱重的Μ. H . P. A. A . A的動物; 4) 口服溶在5%磺酸氳納溶液中的30毫克/千克體重 的A S A的動物; 5) 口服ASA (30毫克/千克龌重)+M. Η. P. A . A . (25毫克/千克體重)的大鼠。 在實驗前2小時服藥。為了誘發局部缺血,將動物用 乙醚輕微麻醉,分離出頸總動脲井並结紮之。然後皮下注 射硝普酸鈉(0. 8毫克/250克腥重 > 迪成低血壓。 濟部中央襻準房員工消费合作社印繫 (請先《讀背面之注意事項再墣寫衣I) 6 0分鐘後取下動脈頭,觀察動物24小時β將它們殺死 ,立即取出大腦,在8 01C的烘箱中放置24小時以確定 含水量。用非參量的Mann-Whitney ϋ檢驗分析結果。上述 劑置的Μ. Η. P. A. Α.和阿斯匹林在分別動物服用 時都不能明顥減輕大腦缺血。但是,當它們一起服用時· 得到明顯的保護作用(Ρ<<〇. 01)(見画17)。 這些結果證實在Μ. Η. P. A. Α.和ASA的抗局部 -39- 本紙張尺度適用t國a家標準(CNS)甲4规格(210 X 297公釐> 299230 A6 B6 五、發明説明() 缺血效能之間有協同作用。 實施例1 9 採 用 兩 種 性 別 的 蒙 古 沙 土 鼠 ( 醞 重 6 0 _ 8 0 克 ) » 事 先 使 其 適 睡 實 驗 室 搽 件 一 周 〇 用 胃 管 飼 法 服 用 懸 浮 在 T« Feen- ‘20水 溶 液 載 劑 中 的 Μ » Η • Ρ • A 參 A • 〇 將 這 些 動 物 隨 機 地 分 成 以 下 幾 组 • 1 ) 限 性 對 照 ( 结 紮 的 動 物 » 只 服 用 載 劑 ) • 2 ) Μ • Η • Ρ • A • A • ( 5 0 毫 克 / 千 克 醞 重 ) > 3 ) Μ • Η • Ρ • A • A • ( 3 0 0 毫 克 / 千 克 龌 重 ) 〇 所 有 治 療 藥 物 都 在 誘 發 大 腦 缺 血 前 2 小 時 服 用 〇 將 在 項 總 頸 動 脈 暴 露 > 在 乙 醚 麻 醉 下 用 外 科 手 術 雙 重 结 紮 P 觀 察 各 動 物 的 行 為 2 4 小 時 t 記 錄 大 腦 缺 血 的 臨 床 症 狀 » 例 如 轉 圈 » 周 而 復 始 的 痙 孿 以 及 癲 癇 等 0 同 時 記 錄 死 亡 率 0 用 Fi s C he Γ 正 合 槪 迕 檢 驗 法 统 計 比 較 各 組 死 亡 率 和 豳 床 症 狀 的 頻 度 〇 结 果 表 明 » 這 種 治 療 減 輕 了 臨 床 症 狀 並 且 大 大 降 低 了 死 亡 率 ( 見 圈 1 8 ) 〇 眾 所 周 知 9 在 结 紮 頸 结 動 脲 之 後 約 6 0 % 的 滎 古 沙 土 鼠 産 生 了 神 經 病 態 缺 陷 » 例 如 轉 圈 ρ 為 和 周 期 性 痙 擊 〇 逭 些 症 狀 與 約 2 / 3 這 ΙΆ 動 物 的 顱 底 點 和 頸 動 脲 % 统 之 間 的 連 结 動 脲 不 完 菩 或 不 存 在 有 鼷 〇 另 外 幾 乎 8 0 % 的 顯 示 經濟部中央標準局典工消费合作社印製 (請先閱讀背面之注意事項再填寫本買) 出臨床症狀的動物在結紮後7 2小時内死亡。 因為難以趣定全部腦區大腦梗塞形成的藤重程度,而 死亡率則容易定量判定,所以通常用此參量評價被認為是 -40- 本紙張尺度適用中國國家標準(CNS)甲4规格(210 X 297公釐) 經濟部中央標準局R工消費合作社印製 A6 __B6_ 五、發明説明() 局部缺血的藥物。我們的结果表明,Μ. Η. P. A. A .(200毫克/千克體重)對蒙古沙土鼠因一側结紮頸 總動脈造成的腦體缺血有明顯的保護作用。因此,說明Μ .Η. Ρ· A. Α.可用於防止腦體缺血的産生。 實施例2 0 研究了Μ. Η. P.A. A.寺各種藥物誘發的费潰 瘍的影逛。使用體重200至220克的兩種性別的 Sprague Dawley大鼠。使動物適睡簧驗室條件一周,水和 食物任意。在24小時禁食之後,將鼠隨機地分成兩傾簧 驗组。第一组在腹膜内注射懸浮在Tween 20/水載劑中的 M . H . P. A. A. (25毫克/千克g重),第二组 (對照组)只接受相同體積的載劑。在每種情形裡,都對 對照组和治療組進行誘發不同類型的藥物誘致異潰瘍的實 驗步缀(毎類潰瘍使用兩组): A )用C 4 8 8 0 ( Sigaa) 實驗誘發的S潰瘍。實驗步 想與 Awouters F·,Nesiegeens CJE和 Jansken PAJ 所 述的相似( 1985 :大鼠肥大细胞5 — HT费損傷試驗 的藥理分析和氟哌喹酮的影鬱;Drug. Div. Res. 5, 303-312) ^ 為此,皮下注射10毫克/千克β重的 聯苯羥基胺,30分鐘後靜脈内注射C4880。在 施用C4880 4小時後將動钧殺死,迅速取出爾 ,沿長度方向切開S大轚,用蒸脯水洗。然後,暴S 出胃粘膜,用放大鏡測量損傷面積。將結果用顯示損 -4 1- 本紙張尺度適用中國國家標準(CNS)甲4规格(210 X 297公* > ------------------------装^------訂-----《線 (請先閲讀背面之注•項再填寫本頁) 經濟部中央標準房與工消费合作社印製 A6 _______B6_ 五、發明説明() 傷的面積百分數表示。在逭種方式裡,在注射聯苯羥 基胺30分鐘之前服用預療藥物(Μ. Η. P. A. A .或載剤)。 B) 乙酵誘發的潰瘍。試驗步驟按Zengil H、Onik E、 Erean TS和 TS和 Tarker RK所述進行( 1987:ilopnost 和UK 38485對於各種剌激物造成的费粘膜損傷的保護 作用;Prostaglandins Leukotrienes and Medicine, 30,61-67 )。為此,在施用 Μ. Η. P. A. A. 或載劑1小時後,用胃管飼法使大鼠口服40%的乙 醇(1奄升/毎只鼠)。2小時後将鼠殺死,如上所 述定量測定宵潰瘍。 C) ASA誘發的S潰瘍:根據前一節中引用的同一作者 的方法進行試驗。在用Μ. Η. P. A. A.或載_ 處理1小時後,令大鼠口服ASA (100¾克/千 克鳢重)。2小時後将鼠殺死,如上所述測定费潰癌 。用非參量的Uann-Whitney U檢驗法比較對照组和用 Μ. Η. P. A. A.處理组。腹膜内施用Μ. H. P.A.A. (25毫克/千;體重)頭著抑制了由 C4880、乙酵和ASA誘發的胃潰瘍(見圔19 )。 另外,正如可以從表19看到的,口服Μ. Η. P, A. A.不僅減少了 TxBz ,而且也使Pg 12增加, 從而大大地降低了 TxB2與Pg IZ之比。 -42- 本紙張尺度適用中a國家標準(CNS> τ 4规格(210 X 297公釐) ----------------一--------装------訂-----^線 (請先閲讀背面之注意事項再堉寫本頁) 經濟部中央標準渴R工消费合作社印製 A6 B6 五、發明説明() 表19:Μ. Η· P. A. A.和ASA對小鼠血淸中 TxBz含量和6酮PsF 1 a的影響 τ X B2 6酮 PgFla Tx B2 (纳克/¾升) (纳克/毫升) 6酮PgFla 對 照 286+16.7 1.65+0.26 173The Mann-Whitney U test statistically scored the results. M.H.P.A. mild cerebral edema (P < < 0. 0.5) at 0 mg / kg body weight. This mortality rate and the percentage of animals with edema, although otherwise to a significant level. These findings indicate that the protective effect of M.H.P.A.A. taking 2 on experimentally-induced moths is greatly reduced, because the brain edema is greatly reduced, showing that the percentage of brain edema and face mark has also been reduced to a significant level (see Table 18). PAA on large and evoked cerebral ischemia Please read the notes on the back before filling the nest. Percentage of the agent placed in the experimental group (mg / kg) Edema dead animal (_) control 0 79.3 +/- 0.39---(+) control 0 80. 1 + /- 0.82 35 54.5 M. H. P. A. A. 5 80 .0 + / -0. 9 1 40 33.3 MHPAA 25 79. 5 + /-0 .49 # 28 7. 6 (_) Control: negative control; (+) Control: Positive control: X is significantly different from the positive control; P < < 0.05 (Mann-Whitney U-38- This paper scale is applicable to China National Standards (CNS) A 4 specifications (210 X 297 mm) A6 _ B6_ V. Description of the invention () test). Example 18 To study the synergistic effect of Μ.Η.PAA and aspirin on induced cerebral ischemia in rats, it will weigh 250 to 300 Gram male Sp 1: ague D a η 1 ey mice are divided into 5 groups 1) Negative control (unligated mice); 2) Positive control (ligated animals that only take the vehicle); 3) Oral administration by tube feeding 25 Mg / kg of M.H.PA A.A. animals; 4) Orally dissolved in 5% sulfonate Animals with 30 mg / kg body weight of A S A in acid radon solution; 5) Oral ASA (30 mg / kg body weight) + M.H.P.A.A. (25 mg / kg body weight) rats. Take the medicine 2 hours before the experiment. To induce ischemia, the animals were lightly anesthetized with ether, and the urea well was isolated and ligated. Then subcutaneously inject sodium nitroprusside (0.8 mg / 250 g fishy weight> Dicheng hypotension. The Department of Economics and Development of the Central Co., Ltd. of the Ministry of Economic Affairs of the Ministry of Economic Affairs (Please read "Precautions on the back and then write I") After 60 minutes, the arterial heads were removed, and the animals were observed to kill them by β for 24 hours. The brains were immediately removed and placed in an oven at 801C for 24 hours to determine the water content. The results were analyzed using non-parametric Mann-Whitney ϋ test. The dosage of M.H.PA Α. And aspirin were not able to relieve cerebral ischemia when they were taken in separate animals. However, when they were taken together, they obtained obvious protective effects (Ρ < < 0.01. ) (See picture 17). These results confirm that the anti-locality in Μ.Η.PA Α. And ASA-39- This paper scale is applicable to the national standard (CNS) A 4 specifications (210 X 297 mm> 299230 A6 B6 V. Description of the invention () There is a synergistic effect between the ischemic effects. Example 1 9 Mongolian gerbils of two genders are used (weight 6 0 _ 8 0 g) »Make it suitable for sleeping in the laboratory for a week 〇Suspension in T «Feen- '20 by gastric tube feeding Μ »Η • Ρ • A in Aqueous Solution Carriers A and A • 〇 Randomly divide these animals into the following groups • 1) Restricted control (ligated animals» only take vehicle) • 2) Μ • Η • Ρ • A • A • (50 mg / kg weight) > 3) Μ • Η • Ρ • A • A • (300 mg / kg weight) 〇All therapeutic drugs are 2 hours before inducing cerebral ischemia Taking 〇 will be exposed in the total carotid artery> Double ligation under ether anesthesia with surgery P Observe the behavior of each animal 2 4 hours t Record the clinical symptoms of cerebral ischemia »For example, circle» Recurrent spasms and epilepsy etc. 0 Simultaneously Record the mortality rate 0. Use the Fi s C he Γ positive and negative test method to statistically compare the mortality rate of each group and the frequency of bed symptoms. The results show that this treatment reduces clinical symptoms and greatly reduces the mortality rate (see circle 1 8 ) 〇 It is well known that about 60% of Xinggu gerbils develop neuropathic defects after ligation of the neck and urea. For example, the circulatory ρ is and periodic spasm. There are some symptoms with about 2/3 of the animal ’s skull base and Cervical urea% The connection between the system and the urea is not complete or there is no 銆. In addition, almost 80% of the display is printed by the Ministry of Economy Central Standards Bureau Code Industry Consumer Cooperative (please read the precautions on the back before filling in this purchase ) Animals with clinical symptoms die within 7 2 hours after ligation. Because it is difficult to determine the degree of vine weight formed by cerebral infarction in all brain regions, and the mortality rate is easy to determine quantitatively, this parameter is usually used to evaluate it as -40- This paper scale is applicable to the Chinese National Standard (CNS) A 4 specification (210 X 297 mm) A6 __B6_ printed by R Industry and Consumer Cooperative, Central Bureau of Standards, Ministry of Economic Affairs V. Description of invention () Ischemic drugs. Our results show that M.H.P.A.A. (200 mg / kg body weight) has a significant protective effect on cerebral ischemia caused by ligating the common carotid artery on one side of the Mongolian gerbil. Therefore, it shows that M.Η.Ρ · Α.Α. Can be used to prevent the occurrence of cerebral ischemia. Example 20 The shadow of various drug-induced Fischer ulcers of M.H.P.A.A. Temple was studied. Sprague Dawley rats of two genders weighing 200 to 220 grams were used. Allow animals to sleep for a week in laboratory conditions, with water and food free. After fasting for 24 hours, the rats were randomly divided into two tilting spring test groups. The first group was injected intraperitoneally with M.H.P.A.A. (25 mg / kg g weight) suspended in Tween 20 / water vehicle, and the second group (control group) received only the same volume of vehicle. In each case, the control group and the treatment group were tested with different types of drugs to induce different ulcers (two groups for each type of ulcer): A) S induced by C 4 8 8 0 (Sigaa) experiment ulcer. The experimental procedure is similar to that described by Awouters F ·, Nesiegeens CJE and Jansken PAJ (1985: Pharmacological analysis of the rat mast cell 5-HT fee injury test and the effect of haloperidone; Drug. Div. Res. 5, 303-312) ^ To this end, 10 mg / kg β-benzylhydroxylamine was injected subcutaneously, and C4880 was injected intravenously 30 minutes later. After 4 hours of application of C4880, Dongjun was killed, and he was quickly taken out. S Daqi was cut along the length and washed with steamed preserved water. Then, burst the gastric mucosa and measure the damaged area with a magnifying glass. Use the results to show the loss-4 1- This paper scale is applicable to the Chinese National Standard (CNS) A 4 specifications (210 X 297 g * * -------------------- ---- Installed ^ ------ Ordered ----- "Line (please read the notes on the back first and then fill in this page) A6 _______B6_ printed by Central Standard Housing and Industrial and Consumer Cooperative of the Ministry of Economic Affairs 5. Invention Explanation () The percentage of the injured area is expressed. In the previous method, the pre-medication (M. Η. PA A. or 艤) was taken 30 minutes before the injection of biphenylhydroxylamine. B) Bacteria-induced ulcer. The test procedure was carried out as described by Zengil H, Onik E, Erean TS and TS and Tarker RK (1987: ilopnost and UK 38485 to protect against mucosal damage caused by various stimulants; Prostaglandins Leukotrienes and Medicine, 30, 61-67 ). For this purpose, rats were orally administered 40% ethanol (1 l / each mouse) by gastric gavage 1 hour after administration of Μ.Η.Ρ.Α.A. or vehicle. After 2 hours, the rats were killed, and the night ulcer was quantitatively determined as described above. C) ASA-induced S ulcers: tested according to the method of the same author cited in the previous section. After 1 hour of treatment with M.H.P.A.A. or Zyzae, rats were orally administered ASA (100¾ g / 1000 g snakehead weight). After 2 hours, the rats were killed, and the cancer was determined as described above. The non-parametric Uann-Whitney U test was used to compare the control group with the M.H.P.A.A. treatment group. Intraperitoneal administration of M.H.P.A.A. (25 mg / kilogram; body weight) inhibited gastric ulcers induced by C4880, ethyl yeast and ASA (see 圔 19). In addition, as can be seen from Table 19, oral administration of M.H.P, A.A. not only reduced TxBz, but also increased Pg 12, thereby greatly reducing the ratio of TxB2 to Pg IZ. -42- This paper scale is applicable to China National Standard (CNS> τ 4 specifications (210 X 297 mm) ---------------- 一 -------- 装------ Subscribe ----- ^ Line (please read the notes on the back before writing this page) A6 B6 printed by the Central Standard of the Ministry of Economy, R, R, and Consumer Cooperatives V. Invention description () Table 19: Μ. Η · PAA and ASA on mouse blood TxBz content and 6 ketone PsF 1 a τ X B2 6 ketone PgFla Tx B2 (ng / ¾ liter) (ng / ml) 6 ketone PgFla control 286+ 16.7 1.65 + 0.26 173

ASA (50毫克 36 · 3+13 . 3**(a) 1. 12 + 0.41 46.5 /千克) M . H . P · A . A . (180¾ 克 182 + 3 1 . 9M (b) 3.91 + 0.4* 32.4 /千克) Μ . Η . P . A . A . + ASA 9.25+5.4*»(c) 1.57+0.16 5.8 # P < 0 , 0 5 ; * * P < 0 . 0 1; a = b = c (M a η n W h i t h e y U 檢驗) 由Μ. Η. P. A. A.引起的對TxBz含量的抑 制和Pg 12的增加可以解禪該混合物對爾潰思的保護作 用。因此,當同時用Μ. Η. P. A. A.和ASA時, 觀察到TxBz對Pg 12之比大;A:減少。另外,這一機 制也可以解釋醇混合物對其它蕖物誘發的费潰瘍的作用。 實施例2 1 對於年龄從2 5到7 0崁的兩種性別患I型高血脂蛋 白的45名門診病人,在雙盲條件下一天一次服用Μ. Η .P. A. Α.或無效對照錠爾6週(治療的病人毎天服 -43- 本纸張尺度適用中國a家標準(CNS)甲4规格(210 X 297公货) (請先閲讀背面之注項再塡寫本I) •裝. 訂· 經濟部中央標準局R工消费合作社印货 Α6 Β6 五、發明説明() 用5毫克Μ. Η. P. A. A.)。在治療前和治療後研 究以下參置:出血時間、血小板計數、凝血酶原時間、抗 凝血酶K活性、溶血時間、血漿優球蛋白、膝苷二磷酸誘 發的血小板聚集度和一丙二醛(MDA)澳度。 表20總結了數據。這些數據表明,與凝固過程有鼷 的參量沒有一齒受到影辑,而在由膝苷二磷酸誘發血小板 聚集的各组之間有顯著差別。另外,也觀察到丙二醛的不 很明顯的減少(P=〇. 058)。 表20··Μ. Η. P. A. A.治療對患I型血脂蛋白過 多的病人血液凝固和血小板聚集的影響 分析時間 無效對照劑 M.H.P.A.A. (5毫克/天) 出血時間 0 2,4 7 ” + / - 1 ’ 2 S ” 2,31 ” + /-1,24” 6周 2,10" + /- .1,34” 1' 08"+/-1,06" 血小板計數 0 201.23 + /- 29.98 1 98 . 1 3 + /- 3 9 . 48 S周 188.55 + /-35 . 99 175.33+/-40.87 凝血菌原時間 0 13.67+/- 1.80 14.43+/- 4.18 S周 13.40+/- 1.10 13 . 69 + /- 2 . 25 鐵維蛋白原 0 2.64+/- 0.46 2.84+/- 0.54 6周 2.81+/- 0.52 2.92+/- 0.44 抗凝血酶I活性0 79.95+/- 7.50 82.86 + /- 1 1 . 9 7 6周 91.78+/· 9.69 9 3 . 6 7 + /- 14 . 6 2 溶血時間 0 247 . 27 + /- 3 0 . 10 230.43+/-48.19 -44- 衣紙張尺度通用中國國家標华(CNS)甲4规格(210 X 297公货> ----------------(--------裝丨-----訂-----(冰 (請先閲面之注項再^^本I) 五、發明説明( 血漿優球蛋白 腺苷二磷酸 丙二醛 a P = 0.058 A6 B6 δ周 248.64+/-55.72 0 35 . 79 + /- 18 . 18 6 周 47.59 + Λ21.29 0 48.98+/-16-28 6周 56.97+/-24.77 0 2.99+/- 1.75 6周 2.79+/-1.28 228.48 + /-45 .39 3 6 . 9 3 + /- 2 0 . 9 3 30 · 98 + /- 24 ‘ 19 52.27+/-24.26 27.45+/-24.81»# 2.45+/- 2.31 1.76+/- 1.67 趣濟部中央襟準馮β:工消費合作社印製 + p < 0.05 + + p < 0 . 0 1 (W a η n W h i t n e y U 檢驗) 實施例2 2 口服或腹膜内施用Μ. Η. P. A. A.顯著增強雄 鼠的性功能。例如,將雄性大鼠隨機地分成3傾實驗组, 適應實驗搽件一周。在處理前測定與接受雌激素的雌®的 交配活性,以保證處理的隨機化分配。一旦證實之後,用 管飼法使大鼠口服Μ. Η. P. A. A.或載劑10周, 處理後再記錄交配活性(見表21)。 表21 :Μ. Η. P. A. A.對ί|鼠性功能的彩堪 組 別 大鼠數目(對SD) 顯示以下行為的大鼠 百分數(% ) 爬上交配 勃起 爬上交配 勃起 對 照 8+14 8+13 50 66 M.H.P.A.Α. 45 本紙張尺度適用中國國家標準(CNS)甲4规格(210 X 297公釐> ----------------(--------裝------訂-----(f <請先閲讀背面之注$項再本頁) A6 _B6_ 五、發明説明() 75 92# 21+21# 22+21: 75 Μ. Η 24+19=» 3 7 + 44#* 83 50 23+11* 23+10*## 100 經濟部中央標攀扃W工消费合作社印« 100* 此表列出了爬上交配和陰莖勃起的平均值+揉準偏差 以及頭示出兩種行為的動樹百分數。用Mann Whitney U檢 驗法對各组的平均值作了比較,並且用fischer的正合概 率檢驗比較了毎種行為發生的頻度。 在處理俸止6周後記錄性功能。未發現各组間還有顯 著差別,因此說明有效處理期間觀察到的雄性性功能增強 與藥物有闋。但是,未觀察到回縮效應。這些结果表明, Μ. Η. P. A. A.造成的性功能的增強在消除期之後 是可逆的。 實施例2 3 研究Μ. Η. P. A. A.對雄猴 (彌猴屬,熊 總科)性行為的影礬。將動物随機#分成下列幾组··一餾 對照组和分別用2. 5和25牽克/千克醮重Μ. Η. P .A.A. 口服處置的2傾组。表22中列出了數據。 表22:Μ. Η. P. A. A.對彌猴交配外性行為和血 清中畢酮含量的影谨(S + SD) 组別 蓽酮含量 -4 6 - p < 0.05; *** ρ<〇·〇01 (在組間比較) <請先HiMe面之注意事項再填寫本買) 訂- 本紙張尺度適用中國國家標準(CNS)甲4规格(210 X 297公* > A6 B6 五、發明説明() (毫克/千克) 勃起數目 對照 2+1 M.H.P.A.A.2.5 12+10 M.H.P. A.A.25 11+ 7 手淫者數目 2+1 10 + 9 7 + 5 (毫莫耳/升) 19.25+6.98 22.00+2.44 16.58^4.44 經濟部中央標準局R工消费合作社印製 «Ρ < 0.05;與對照組比較(Hann Whitney ϋ檢驗) 结果表明,Μ. Η. P.A. Α.顯著增強被控制雄 猴的交配外性活動,因為陰莖勃起和手淫者的數目比對照 組顯箸增加。但是,處置组和對照組之間的血淸畢酮含量 之間沒有重大差別。此實施例說明,服用這些製劑增強所 處置的動物的性功能,而逭一效果與在猴子中發現的雄性 激素含量無關。猴子的一般行為的其它部分未受影《。這 表明Μ. Η. P. A. A.的這種刺激作用主要不是作用 在中植神經条統上,而是作用在末梢效應器上。考慮到Μ .Η. P. A. Α.對ΤχΑ2與Pgl2之比的影《, 不能排除一氣化氮(NO)的釋放剌激陰莖海綿體是造成 這一作用的機制。 實施例2 4 如上所述,M . H . P 行為。因為二十八烷醇是Μ 分,比較了二十八烷酵和Μ 地對雄性大罝性行為的影鬱 A .A .刺 激 雄 性 大 m 的 性 Η .P .A • A • 的 主 要 組 Η .P .A • A » 各 白 單 獨 使 W i s ta r雄 鼠 和 雌 鼠 適 應 實 2 周將 雌鼠 卵 m 切 1 除 〇 為 進 — 8 0 小時 皮 下 注 私 0 5 本纸張尺度適用中國國家標準(CNS)甲4规格(210 X 297公釐) ----------------(-------裝------訂-----(球 (請先聞讀背面之注意事項再填寫本頁> 經濟部中去櫺準场R工消费合作社印製 A6 ___^__B6_ 五、發明説明() 毫克/千克匾重的苯甲酸雌二醇酯,5 — 8小時前注射磺 g嗣。將Μ. Η. P. A. A.懸浮在Tween 20水質中, 腹膜内注射3周。二十八烷醇以類似的方式製備和施用。 對照動物只施用載剤。 將動物隨機地分成三组:⑴對照组,⑵Μ. Η. P. A. A.组(1. 54毫克/千克體重)和⑶二十八烷 醇組(1毫克/千克體重)。考慮到二十八烷醇在溫合物 中的相對狸度,上述的劑量保證了二十八烷醇在所處置的 兩组中劑量相同。在基線處(保證各組的性功能充分随機 化)和處置3周後觀察交配活性。記錄下由受醞雌與激發 的陰莖勃起和爬上交配行為共90分種。採用Mann Whiteny U檢驗法對各組進行比較。在基線處,所有各組 的性功能相近,但在處置3周以後,所處置的兩組中勃起 和爬上交配的數目明顯高於對於組。另一方面,在Μ. Η .P. A. Α.組中爬上交配和勃起的數目比二十八烷酵 組中的高得多(見表23)。 這些结果與先前的顯示酵混合物激發雄鼠性行為的结 果相一致,但是它邇顯示了二十八烷醇誘發的剌激作用。 但是,用醇混合物處置组比二十八烷醇組的性行為明顯要 高。它表明,醇混合物的剌激作用與二十八烷醇的存在有 闢,但是混合物中其它醇的存在货定以某種方式調節對性 功能的剌激作用。 表23:Μ. Η. P. A. Α.和二十八烷醇對雄性大鼠 -4 8 _ ----------------一-------装------訂------- (請先聞讀背面之注$項再填寫本頁) 本紙張尺度適用中BS家標準(CNS)甲4規_樁(210 X 297 > A6 B6 五、發明説明() 性行為的影鬱 組 別ASA (50 mg 36 · 3 + 13.3 ** (a) 1. 12 + 0.41 46.5 / kg) M. H. P · A. A. (180¾ g 182 + 3 1 .9M (b) 3.91 + 0.4 * 32.4 / kg) Μ. Η. P. A. A. + ASA 9.25 + 5.4 * »(c) 1.57 + 0.16 5.8 # P < 0, 0 5; * * P < 0. 0 1; a = b = c (M a η n W hithey U test) The inhibition of TxBz content and the increase of Pg 12 caused by Μ.Η.PAA can relieve the protective effect of this mixture on Erkui. Therefore, when M.H.P.A.A. and ASA were used at the same time, a large ratio of TxBz to Pg 12 was observed; A: decreased. In addition, this mechanism may also explain the effect of alcohol mixtures on other ulcer-induced Fischer ulcers. Example 2 1 For 45 outpatients with type I hyperlipoproteins from two genders ranging from 25 to 70 years old, taking M.H.PA Α. Or invalid control tablets 6 once a day under double-blind conditions Zhou (Treatment of patients every day service-43- This paper scale is applicable to China's a standard (CNS) A4 specifications (210 X 297 public goods) (please read the notes on the back and then write down I) • Install. Order · Printed goods Α6 Β6 by the R-Consumer Cooperative of the Central Bureau of Standards of the Ministry of Economic Affairs V. Description of invention () 5 mg Μ.Η.PAA). The following parameters were studied before and after treatment: bleeding time, platelet count, prothrombin time, antithrombin K activity, hemolysis time, plasma globulin, ganglioside diphosphate-induced platelet aggregation, and one-propane di Aldehyde (MDA) Australia. Table 20 summarizes the data. These data indicate that none of the parameters related to the coagulation process are affected, and there is a significant difference between the groups induced by platelet aggregation induced by ganglioside diphosphate. In addition, an insignificant reduction in malondialdehyde was also observed (P = 0.058). Table 20 ·· M.H. Effect of PAA treatment on blood coagulation and platelet aggregation in patients with hyperlipoprotein type I Analysis time Ineffective control agent MHPAA (5 mg / day) Bleeding time 0 2, 4 7 "+ /-1 '2 S ”2,31” + / -1,24 ”6 weeks 2,10 " + /-.1,34” 1' 08 " +/- 1,06 " Platelet count 0 201.23 + /-29.98 1 98 . 1 3 + /-3 9. 48 S weeks 188.55 + / -35. 99 175.33 +/- 40.87 prothrombin time 0 13.67 +/- 1.80 14.43 +/- 4.18 S weeks 13.40 +/- 1.10 13. 69 + /-2. 25 pro-ferritin 0 2.64 +/- 0.46 2.84 +/- 0.54 6 weeks 2.81 +/- 0.52 2.92 +/- 0.44 antithrombin I activity 0 79.95 +/- 7.50 82.86 + /-1 1 . 9 7 6 weeks 91.78 + / · 9.69 9 3. 6 7 + /-14. 6 2 Hemolysis time 0 247. 27 + /-3 0. 10 230.43 +/- 48.19 -44- General Chinese national standard for clothing and paper China (CNS) A 4 specifications (210 X 297 public goods> ---------------- (-------- install 丨 ----- order-- --- (Bing (please read the notes first and then ^^ this I) V. Description of the invention (Plasma euglobulin adenosine diphosphate malondialdehyde a P = 0.058 A6 B6 δweek 248.64 +/- 55.72 0 3 5.79 + /-18.18 6 weeks 47.59 + Λ21.29 0 48.98 +/- 16-28 6 weeks 56.97 +/- 24.77 0 2.99 +/- 1.75 6 weeks 2.79 +/- 1.28 228.48 + / -45. 39 3 6. 9 3 + /-2 0. 9 3 30 · 98 + /-24 '19 52.27 +/- 24.26 27.45 +/- 24.81 »# 2.45 +/- 2.31 1.76 +/- 1.67 Central Department Quasi-Feng β: Printed by the Industrial and Consumer Cooperative Society + p < 0.05 + + p < 0. 0 1 (W a η n W hitney U test) Example 2 2 Oral or intraperitoneal administration of Μ.Η.PAA significantly enhanced male Sexual function of rats. For example, male rats are randomly divided into 3 tilt experimental groups and adapted to the experiment for a week. Before mating, the mating activity with estrogens receiving estrogen was measured to ensure randomized distribution of treatment. Once confirmed, the rats were orally administered M.H.P.A.A. or vehicle for 10 weeks by gavage, and the mating activity was recorded after treatment (see Table 21). Table 21: Μ. Η. PAA on the number of rats in the color-can group of sexual function (for SD) Percentage of rats showing the following behavior (%) Climbing up to mating erection Climbing up to mating erection control 8 + 14 8+ 13 50 66 MHPAΑ. 45 This paper scale is applicable to China National Standard (CNS) A 4 specifications (210 X 297 mm > ---------------- (----- --- installed ------ order ----- (f < please read the note $ item on the back and then this page) A6 _B6_ V. Description of invention () 75 92 # 21 + 21 # 22 + 21 : 75 Μ. Η 24 + 19 = »3 7 + 44 # * 83 50 23 + 11 * 23 + 10 * ## 100 Ministry of Economic Affairs Central Standard Pan Weng Wong Consumer Cooperatives Cooperative« 100 * This table lists the climb The average value of mating and penile erection + the deviation of the pinching and the percentage of moving trees showing the two behaviors. The average value of each group was compared using the Mann Whitney U test, and the Fischer ’s probability of coincidence test was used to compare each. The frequency of these behaviors. Sexual function was recorded after 6 weeks of treatment. No significant differences were found between the groups, thus indicating that the enhancement of male sexual function observed during the effective treatment was associated with the drug. However, no return was observed Shrinkage effect. These The results show that the enhancement of sexual function caused by Μ.Η.PAA is reversible after the elimination period. Example 23 3 Study the influence of Μ.Η.PAA on the sexual behavior of male monkeys (Mice monkeys, Ursidae). The animals were randomly divided into the following groups ... A single-control group and a 2-dip group treated orally with 2.5 and 25 gram / kg weight M.H.P.AA, respectively. Table 22 lists the data. Table 22: M.H.PAA's effect on the sexual behavior of baboon monkeys during mating and the content of serum ketone (S + SD) group hormonone content-4 6-p <0.05; *** ρ < 〇.〇 01 (Compare between groups) < Please note the HiMe first, then fill out the purchase. Order-This paper scale is applicable to the Chinese National Standard (CNS) A 4 specifications (210 X 297 g *) A6 B6 V. Description of the invention () (Mg / kg) Number of erections 2 + 1 MHPAA2.5 12 + 10 MHPAA25 11+ 7 Number of masturbators 2 + 1 10 + 9 7 + 5 (millimol / l) 19.25 + 6.98 22.00 + 2.44 16.58 ^ 4.44 Printed by «P <0.05; R &C; R &C; Cooperative Society, Central Bureau of Standards, Ministry of Economic Affairs; comparison with control group (Hann Whitney ϋ test) The results show that Μ.Η.PA Α. Is significant The male sexual activity of the controlled male monkey was enhanced, because the number of penile erections and masturbation increased significantly compared with the control group. However, there was no significant difference between the treatment group and the control group in the content of blood peptide. This example illustrates that taking these formulations enhances the sexual function of the treated animals, while the Yi Yi effect is not related to the androgen levels found in monkeys. The rest of the monkey's general behavior is unaffected. This indicates that the stimulating effect of M.H.P.A.A. is mainly not on the medullary nerve system but on the peripheral effector. Considering the effect of Μ.Η.P.A.Α. on the ratio of ΤχΑ2 to Pgl2, it cannot be ruled out that the release of nitric oxide (NO) stimulates the penis corpus cavernosum as the mechanism causing this effect. Example 24 As described above, M.H.P acts. Since octacosanol is a M component, the effect of octacosanol and M on the sexual behaviors of males in large rice A.A. is the major group that stimulates the sex of males m.P.A • A • .P .A • A »Each white adapts the male and female Westar rats to 2 weeks. Divide the female mouse m by 1 and divide it into 〇 for progress — 80 hours subcutaneous injection 0 5 This paper size is suitable for China National Standard (CNS) A 4 specifications (210 X 297 mm) ---------------- (------- installed ------ ordered --- -(Ball (please read the precautions on the back first and then fill out this page> A6 ___ ^ __ B6_ printed by the Ronggong Consumer Cooperative of the Ministry of Economic Affairs of the Ministry of Economic Affairs. V. Description of invention () mg / kg plaque weight benzoic acid Estradiol ester, 5-8 hours before injection of sulfonamide. Suspended M.H. PAA in Tween 20 water and injected intraperitoneally for 3 weeks. Octadecanol was prepared and administered in a similar manner. Control animals only Administration of the carrier. The animals were randomly divided into three groups: ⑴ control group, ⑵M. Η.PAA group (1.54 mg / kg body weight) and ⑶ octacosanol group (1 mg / kg body weight). Considering The relative dose of octadecyl alcohol in the temperature compound, the above doses ensure that the dose of octacosanol is the same in the two groups treated. At the baseline (to ensure that the sexual function of each group is sufficiently randomized) and Observe the mating activity after 3 weeks of treatment. Record 90 minutes of erection and climbing mating behaviors between the gestated female and the excited penis. Mann Whiteny U test method was used to compare each group. At the baseline, the sex of all groups The function is similar, but after 3 weeks of treatment, the number of erections and climbing matings in the two groups treated is significantly higher than for the group. On the other hand, the number of climbing matings and erections in the Μ.Η.PA Α. Group Much higher than in the octacosane yeast group (see Table 23). These results are consistent with previous results showing that the enzyme mixture stimulated sexual behavior in male rats, but it has shown the octacosanol-induced stimulation However, the sexual behavior of the alcohol mixture treatment group is significantly higher than that of the octacosanol group. It shows that the stimulating effect of the alcohol mixture is incompatible with the presence of octacosanol, but the presence of other alcohols in the mixture is ordered Adjust the pair in some way Functional stimulation. Table 23: Μ.Η.PA Α. And octacosanol on male rats-4 8 _ ---------------- 一 --- ---- Installed ------ Ordered ------- (please read the $ item on the back and then fill in this page) This paper size is applicable to the BS family standard (CNS) A 4 regulation _ pile (210 X 297 > A6 B6 V. Description of invention () Shadow depression group of sexual behavior

X + S D 對 照 M.H.P.A.A. 二十八烷醇 爬上交配 44 + 23 175+87*# 81+40* 勃 起 40+19 174+87#* 76 + 37 (請先閲讀背面之注意事項再填寫本頁) 經濟部中央標準局貝工消费合作社印製 -49- 本紙張尺度適用中國國家標準(CNS)甲4规格(210 X 297公* ) 經濟部中央標準局員工消费合作社印製 A7 B7 1固醇正常的家兔血清膽固醇含量 \ P < 0.05 (Mann Whitney U 試 -一. A .爾血膽固醇正常的家兔血清LDL-C含量 的影響,其中 * 為 P < 0.05 (Mann Whitney U 試 驗)。 画3 : M.H.P.A.A.對血膜固醇正常的家兔血清瞻固醇變化 (%)的影镳,其中 >:< 為 P < 0.05 (Mann Whitney U試驗)。 圖4 : M.H.P.A.A.對血膽固醇正常的家兔血清LDL-C變化 (%)的影逛,其中 * 為 P < 0.05 (Mann Whitney U試驗)。 圖5 : M.H.P.A.A.對血膽固醇正常的家兔血清LDL-C含量 的影饗。 圖6 : M.H.P.A.A.對血膽固醇正常的家兔血清甘油三酯的 影蜜。X + SD vs. MHPAA octacosanol climb up to mating 44 + 23 175 + 87 * # 81 + 40 * erection 40 + 19 174 + 87 # * 76 + 37 (please read the notes on the back before filling this page) Printed by the Beigong Consumer Cooperative of the Central Bureau of Standards of the Ministry of Economic Affairs-49- This paper scale is applicable to the Chinese National Standard (CNS) A 4 specifications (210 X 297 g *). The A7 B7 1 sterol is printed by the Consumer Cooperative of the Ministry of Economic Affairs The serum cholesterol content of rabbits \ P < 0.05 (Mann Whitney U test-I. A. The effect of serum LDL-C content in rabbits with normal blood cholesterol), where * is P < 0.05 (Mann Whitney U test). Picture 3: The effect of MHPAA on the serum sterol change (%) in rabbits with normal blood plasma sterols, where >: < is P < 0.05 (Mann Whitney U test). Figure 4: MHPAA on blood cholesterol The effect of normal rabbit serum LDL-C changes (%), where * is P < 0.05 (Mann Whitney U test). Figure 5: The effect of MHPAA on the serum LDL-C content of rabbits with normal blood cholesterol. Figure 6: The effect of MHPAA on the serum triglyceride of rabbits with normal blood cholesterol.

圖7 : M.H.P.A.A.對血膽固醇正常的家兔血清甘油三酯變 化的影谨,其中*為 P < 0.05 (Mann Whitney U 試驗)。 圖8 : M.H.P.A.A.對ϋ型血脂蛋白過多患者之血脂分佈的 影響。 圖9 :服用Μ.Η.Ρ.Α.Α.—個月的大鼠腺苷二磷酸誘發的血 -5 1- 本紙伕尺度適用中國國家標準(CNS ) Α4規格(210X 297公釐)Figure 7: Effect of M.H.P.A.A. on serum triglyceride changes in rabbits with normal blood cholesterol, where * is P < 0.05 (Mann Whitney U test). Figure 8: The effect of M.H.P.A.A. on the distribution of blood lipids in patients with hyperlipoproteinemia type ϋ. Figure 9: Rat adenosine diphosphate-induced blood after taking Μ.Η.Ρ.Α.Α. for one month -5 1- This paper size is applicable to the Chinese National Standard (CNS) Α4 specification (210X 297 mm)

Hi______丁 ^ nn nn av^^i —^ϋ I ί « (請先閱讀背面之注意事項再填寫本頁) 299230 ΑΊ Β7 五、發明説明() 小板聚集,其中 * 為p << 0.05 (Mann Whitney U 試驗);15公分100%透光率。 圖10:服用M.H.P.A.A.—個月的大鼠膠原誘發的血小板聚 集,其中 *為 P << 0.05 (Mann Whitney U 試驗); 1 5公分1 0 0 %透光率。 圖11: Η·Η,Ρ.Α·Α.對大鼠富含血小板血漿中腺苷二磷酸誘 發的血小板聚集,其中*為Ρ << 0 . 0 5 ( M a η η W h i t η e y U 試驗)。 _12: M.H.P.A.A.對濁度為2撤莫耳/升的腺苷二磷酸誘 發的血小板聚集的影鎏,其中*為P << 0.01。 圖13: H.H.P.A.A.對大鼠靜脈内血小板聚集的影鬱,其中 * 為 P < < 0.05; «* 為 p < < 0.01 (Mann Whitney U試驗)。 圖1 4 : M . H . P . A . A .對膠原誘導的C 5 7 B L 6小鼠死亡率的影饗 ,其中 **為 P << 0.01 (Mann Whitney U 試驗)。 圖15 : M.H.P.A.A.對膠原誘導的C57BL6小鼠死亡率的影響 ,其中 * 為 P < < 0 . 0 5 ( M a η n W h i t n e y U 試驗)。 經濟部中央標準局員工消費合作社印製 (請先閱讀背面之注意事項再填寫本頁) 圖1 6 : Μ . Η · P . A . A .和A S A混合服用對膠原誘導的小鼠死亡率 的影響,其中**為 P << 0.01 (Fisher正合機率試 驗)。 圖17: M.H.P.A.A.和ASA對大鼠大腦缺血的協同作用,其中 為 P << 0.01 (Mann Whitney U 試驗)。 圖18: M.H.P.A.A.對誘發的蒙古少土鼠中大腦梗塞的影響 -5 2- 本紙張尺度適用中國國家標準(CNS ) A4規格(210X 297公釐) A7 B7 五、發明説明() ,其中 Μ為 P << 0·05 (Mann Whitney U 試驗)。 圖 對 其 鬱 影 的 瘍 潰 1 的 發 誘 醇 乙 和 (請先閲讀背面之注意事項再填寫本頁) 丄 '-° 經濟部中央標準局貝工消費合作社印製 本紙張尺度適用中國國家標準(CNS ) Α4规格(210X297公釐)Hi______ 丁 ^ nn nn av ^^ i — ^ ϋ I ί «(please read the precautions on the back before filling in this page) 299230 ΑΊ Β7 V. Description of invention () Small board gathering, where * is p < < 0.05 (Mann Whitney U test); 15 cm 100% light transmittance. Figure 10: Platelet aggregation induced by M.H.P.A.A. for one month in rats, where * is P < 0.05 (Mann Whitney U test); 15 cm 100% light transmittance. Figure 11: Η · Η, Ρ.Α · Α. Platelet aggregation induced by adenosine diphosphate in rat platelet-rich plasma, where * is Ρ < < 0.05 (M a η η W hit η ey U test). _12: The effect of M.H.P.A.A. on platelet aggregation induced by adenosine diphosphate with a turbidity of 2 mols / liter, where * is P < < 0.01. Figure 13: H.H.P.A.A.'s effect on rat platelet aggregation in vein, where * is P < <0.05; «* is p < < 0.01 (Mann Whitney U test). Figure 14: M.H.P.A.A. on collagen-induced mortality of C57BLL6 mice, where ** is P < < 0.01 (Mann Whitney U test). Figure 15: Effect of M.H.P.A.A. on collagen-induced mortality in C57BL6 mice, where * is P < 0.05 (M a η n W h i t n e y U test). Printed by the Employee Consumer Cooperative of the Central Bureau of Standards of the Ministry of Economic Affairs (please read the precautions on the back before filling out this page) Figure 16: M.H.P.A.A. and ASA mixed with ASA on collagen-induced mouse mortality Impact, where ** is P < < 0.01 (Fisher positive probability test). Figure 17: Synergy of M.H.P.A.A. and ASA on cerebral ischemia in rats, where P < < 0.01 (Mann Whitney U test). Figure 18: The effect of MHPAA on the induced cerebral infarction in Mongolian gerbils-5 2- This paper scale is applicable to the Chinese National Standard (CNS) A4 specifications (210X 297 mm) A7 B7 V. Description of invention (), where M is P < < 0.05 (Mann Whitney U test). The picture shows the alluring alcohol of Yu Ying 1 (please read the precautions on the back before filling in this page) 丄 '-° Printed by the Beigong Consumer Cooperative of the Central Standards Bureau of the Ministry of Economy. (CNS) Α4 specification (210X297mm)

Claims (1)

經濟部中央標準局貝工消費合作社印袈 六、申請專利範圍 1.一種於用於治療血牖固酵過多、血小板過度聚集 、局部缺血、血栓形成之藥學組成物,其係可與乙醢水楊 酸併用而用於治療血小板過度聚集、局部缺血或血栓形成 、預防藥物引起的漬瘍和/或改菩雄性性功能,其中活性 成分係為高级脂族伯酵組合包含卜二十四烷酵0.5-1.0% ,卜二十六烷醇5.5-8.5%,卜二十t烷醇2.0-3.5%, 卜二十八烷酵60.0-70.0%,卜二十九烷醇0.5-1.2% ’ 卜三十烷酵10.0-15.0%,1-三十二烷醇4.0-6.0%及卜三 十四烷酵0.4-2. 0%,此藥學組成物與乙醢水楊酸的比例 為由20 : 1至1 : 20。 2 ·如申請專利範圍第1項的蕖學組成物,其中高级 脂族伯醇組合包含1-二十四烷醇0.8±0.1%,1-二十六烷 酵6.7 士 0.3%,卜二十七烷酵3.0 土 0.3%,卜二十八烷酵 65.6 土 3.4%,1-二十九烷醇0.7 士 0.1%,卜三十烷醇12.5 土 0.6%,卜三十二烷酵5.0 土 0.4%和1-三十四烷酵0.8 士 0.1%。 3 ·—種製備如申請專利範圍第1或2項藥學組合物 中活性成分的方法,其特徵在於將甘蔗撖於溫度9Q至150 D之間熔化,由3 Q分鐘至1 5小時之時間範圍内用鹼金屬或 鹼土金靥氫氧化物溶液,於氫氧化物濃度為5至30%範圍 間的均質相中皂化,於固一液萃取系統中用有機溶劑,以 1小時至2 0小時範園間萃取高级脂族伯酵,其中此有機溶 本紙張又度逍用t國國家揉準(CNS ) A4規《格(210X297公釐) --------ij 裝------訂------{球 (請先閲讀背面之注意事項再填寫本頁) 經濟部中央標準局負工消費合作社印装 A8 B8 C8 D8 六、申請專利範圍 劑係選自由6至9個碳原子的烴類、由3至8個碳原子的 釅類、由1至5個碳原子的酵類、鹵仿或芳族化合物和/ 或其等之混合物,及選擇性地將粗產物在上述有機溶劑和 /或其混合物中再结晶。 4 ♦如申請專利範圍第3項的方法,其中氫氧化納、 鈣和/或鉀被用為氫氧化物溶疲。 5 *如申請專利範圍第3項的方法,其中戊烷、己烷 、庚烷和/或辛烷被用為萃取步驟中的烴類。 6 ·如申請專利範圍第3項的方法,其中丙酮、戊酮 、甲基乙基嗣、甲基丁基酮和/或3-庚酮被用為萃取步驟 中的酮類。 7 ·如申請專利範圍第3項的方法,其中甲酵、乙酵 、正丙酵、2-丙酵、正丁酵、2-丁酵、正成醇和/或叔丁 酵被用為萃取步驟中的酵類。 8 .如申請專利範圍第3項的方法,其中二氛甲烷、 1,2-二氯乙烷、氯仿、三氯乙烷、1,2-二氯丙烷和/或 1,2,3 -三氯丙烷被用為萃取步驟中的鹵仿。 9 .如申請專利範圍第3項的方法,其中苯、甲苯、 乙苯、苯酚和/或對甲基甲苯被用為萃取步驟中的芳族溶 劑。 1 0 .—種用於治療血臑固酵過多症、及作為抗血小 板劑、抗血栓形成劑、抗局部缺血劑、用為抗胃潰瘍之保 護和/或治療劑、並用Μ改菩人及動物性功能之槩學組成 -2 - 本紙張尺度速用中國國家標準(CNS ) Α4現格(210 X 297公釐) --------η .裝------訂------^ 成 (請先閲讀背面之注意事項再填寫本頁) A8 B8 C8 D8 六、申請專利範圍 物,其可為錠劑、膠囊或粒劑,其特徽在於其中含有Q.5-15.0%重量的申請專利範圍第1或2項的活性成分和作為 藥物賦形劑的50.0-65.0%重量的乳糖,10.0-20.0%重量 的玉米澱粉,3.0-6.0%重量的蔗糖,6.0-10.0 %重量的 微晶纖維素,1.5-4.0%重量的明膠,3.0-7.0%重量的交 聯羧甲基纖維素钠,1.0-3.0%重童的滑石粉和0.5-2.5% 重量的硬脂酸鎂,及選擇性之其他藥用賦形劑。 1 1 ·如申請專利範圍第1項的藥學組合物,其中藥 學組成物與乙醯水楊酸的比例為由1 0 : 1至1 : 1 0。 t 裝 訂 (請先閲讀背面之注意事項再填寫本頁) 經濟部中央樣準局負工消費合作社印製 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐)Beigong Consumer Cooperative of the Central Bureau of Standards of the Ministry of Economic Affairs of the People's Republic of China 腈 六. Application for patent scope 1. A pharmaceutical composition used for the treatment of hyperplasia of blood stasis, excessive aggregation of platelets, ischemia, and thrombosis, which can be combined with beta The combination of salicylic acid is used to treat excessive platelet aggregation, ischemia or thrombosis, prevent drug-induced stains and / or improve male sexual function, in which the active ingredient is a combination of advanced aliphatic primary enzymes containing Bu 24 Alkane fermentation 0.5-1.0%, octacosanol 5.5-8.5%, octacosanol 2.0-3.5%, octacosanol 60.0-70.0%, octacosanol 0.5-1.2% ”Bu thirty thirty enzyme 10.0-15.0%, 1-tridodecyl alcohol 4.0-6.0% and Bu tridecane yeast 0.4-2. 0%, the ratio of this pharmaceutical composition to acetosalicylic acid is 20: 1 to 1: 20. 2. The metabolites composition as claimed in item 1 of the patent application, in which the combination of higher aliphatic primary alcohols contains 1-tetracosyl alcohol 0.8 ± 0.1%, 1-hexacosane yeast 6.7 persons 0.3%, Bu 20 Heptane fermentation 3.0 soil 0.3%, octacosane fermentation 65.6 soil 3.4%, 1-29-alkanol 0.7 ± 0.1%, triacontanol 12.5 soil 0.6%, tridodecane fermentation 5.0 soil 0.4 % And 1-tridecane yeast 0.8 ± 0.1%. 3. A method for preparing the active ingredient in the pharmaceutical composition as claimed in item 1 or 2 of the patent application, characterized in that the sugar cane is melted at a temperature of 9Q to 150 D, and the time range is from 3 Q minutes to 15 hours Internal use of alkali metal or alkaline earth hydroxide solution of samarium, saponification in a homogeneous phase with a hydroxide concentration ranging from 5 to 30%, using an organic solvent in the solid-liquid extraction system, in the range of 1 hour to 20 hours High-grade aliphatic primary leaven is extracted in the garden, and this organically soluble paper is used in the country's national rubbing standard (CNS) A4 regulation "grid (210X297mm) -------- ij installed ---- --Order ------ {ball (please read the notes on the back before filling in this page) A8 B8 C8 D8 printed by the Consumer Labor Cooperative of the Central Standards Bureau of the Ministry of Economic Affairs 6. The range of patent application agents is from 6 to Hydrocarbons of 9 carbon atoms, tinctures of 3 to 8 carbon atoms, yeasts of 1 to 5 carbon atoms, halogenated or aromatic compounds and / or mixtures thereof, and optionally The product is recrystallized in the above organic solvent and / or mixtures thereof. 4 ♦ The method as claimed in item 3 of the patent application, in which sodium hydroxide, calcium and / or potassium are used as hydroxide dissolution. 5 * The method as claimed in item 3 of the patent application, in which pentane, hexane, heptane and / or octane are used as hydrocarbons in the extraction step. 6. A method as claimed in item 3 of the patent application, wherein acetone, amyl ketone, methyl ethyl ketone, methyl butyl ketone and / or 3-heptanone are used as ketones in the extraction step. 7 · The method as claimed in item 3 of the patent application, in which formazan, ethylenzyme, n-propanase, 2-propanol, n-butanol, 2-butanol, n-alcohol and / or tert-butanol are used in the extraction step Of yeast. 8. The method as claimed in item 3 of the patent scope, in which dichloromethane, 1,2-dichloroethane, chloroform, trichloroethane, 1,2-dichloropropane and / or 1, 2,3-tris Chloropropane is used as the haloform in the extraction step. 9. The method as claimed in item 3 of the patent application, wherein benzene, toluene, ethylbenzene, phenol and / or p-methyltoluene is used as the aromatic solvent in the extraction step. 10. It is used for the treatment of hyperlipidemia, as an antiplatelet agent, antithrombotic agent, anti-ischemic agent, as a protective and / or therapeutic agent against gastric ulcer, and it is used together with M Composition of animal sexual function-2-The standard of this paper is the Chinese National Standard (CNS) Α4 present format (210 X 297 mm) -------- η. 装 ------ 定- ----- ^ into (please read the precautions on the back before filling in this page) A8 B8 C8 D8 6. The scope of patent application, which can be tablets, capsules or granules, the special emblem is that it contains Q. 5-15.0% by weight of the active ingredients of the patent application range 1 or 2 and as pharmaceutical excipients 50.0-65.0% by weight of lactose, 10.0-20.0% by weight of corn starch, 3.0-6.0% by weight of sucrose, 6.0 -10.0% by weight microcrystalline cellulose, 1.5-4.0% by weight gelatin, 3.0-7.0% by weight croscarmellose sodium, 1.0-3.0% by weight talcum powder and 0.5-2.5% by weight hard Magnesium fatty acid, and optionally other pharmaceutical excipients. 1 1 • The pharmaceutical composition as claimed in item 1 of the patent application, wherein the ratio of the pharmaceutical composition to acetylsalicylic acid is from 10: 1 to 1:10. t Binding (please read the precautions on the back before filling in this page) Printed by the Consumer Labor Cooperative of the Central Bureau of Prototyping of the Ministry of Economic Affairs. The paper size applies to the Chinese National Standard (CNS) A4 (210X297mm)
TW82101311A 1992-09-29 1993-02-24 TW299230B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU10792 1992-09-29

Publications (1)

Publication Number Publication Date
TW299230B true TW299230B (en) 1997-03-01

Family

ID=51565517

Family Applications (1)

Application Number Title Priority Date Filing Date
TW82101311A TW299230B (en) 1992-09-29 1993-02-24

Country Status (1)

Country Link
TW (1) TW299230B (en)

Similar Documents

Publication Publication Date Title
KR100269844B1 (en) A mixture of higher primary aliphatic alcohols, its obtention from sugar cane wax and its pharmaceutical uses
AU782595B2 (en) High molecular weight primary aliphatic alcohols obtained from beeswax and pharmaceutical use thereof
US6596776B2 (en) High molecular weight primary aliphatic alcohols obtained from natural products and uses thereof
KR100998858B1 (en) Foods and drinks for ameliorating hyperglycemia
JPWO2003068205A1 (en) Obesity treatment agent and food for preventing or improving obesity
US20070281990A1 (en) Methods of using low-dose doxepin for the improvement of sleep
US20090042971A1 (en) Method of using low-dose doxepin for the improvement of sleep
US20090042972A1 (en) Methods of using low-dose doxepin for the improvement of sleep
FR2532843A1 (en) PHARMACEUTICAL COMPOSITION COMPRISING PHYTOL OR ISOPHYTOL AS ACTIVE INGREDIENT
JPH0551388A (en) Lipid peroxide production-inhibiting agent
EP0654262A1 (en) A mixture of higher primary aliphatic alcohols, its obtained from beeswax and its pharmaceutical use
JP2008222656A (en) Obesity ameliorating and preventing composition and health food
TW299230B (en)
JP2005298379A (en) IkappaB KINASE INHIBITOR
JP4164538B2 (en) Visceral fat accumulation inhibitor
US5166200A (en) Treatment of endometriosis
KR100906893B1 (en) Novel piperidin-2,6-dione bisulphate salts and their use for the treatment of stress-related affective disorders
JPH07149628A (en) Improver for lipid metabolism
JP6368270B2 (en) Monieroside A and its derivatives, or a pharmaceutical composition, health food or cosmetic containing the same as an active ingredient
US3193458A (en) Method of lowering blood cholesterol level
JP2002529409A (en) Glucose and lipid lowering compounds
JPH06211713A (en) Antiallergic agent
US3183151A (en) Treatment of hypocholeresis with 1-cyclohexyl-2-methyl-1-propanol
JPS59175425A (en) Vessel strengthening agent
US5082846A (en) Use of the R-(+)-isomer of 2-methoxy-3-octadecyloxy-propanol-(1)-phosphoric acid, monocholine ester in treating multiple sclerosis